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s0010 Introduction
p0010 Host–guest interactions are fundamentally dependent on the shape complementarity of the host and guest molecules. The central
challenge in supramolecular chemistry is therefore to sculpt molecules with a specific geometric arrangement of the atoms and
hence to form the molecular surface necessary for molecular recognition to take place. For hosts, the well-defined shape is most
often achieved by introducing one or more cyclic constraints (molecular baskets and cages or crown ethers) into the molecule, so
that the final molecular surface is already created in the synthetic process. For foldamers, the molecular shape is not a direct product
of chemical synthesis. The oligomeric sequence is first constructed by using a suitable monomer library and coupling methods, and
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the geometry is attained in a subsequent stage depending on the solution conditions and interacting partners, this phenomenon
being known as folding. In this sense, in just the same way as biopolymers, foldamers have a hierarchical structure. For this reason,
the molecular recognition properties have to be engineered within the chain molecule to facilitate folding and thereby to create a
molecular surface predisposed to intermolecular recognition. While the strategy of shape formation differs for foldamers, the
orchestration of all the noncovalent interactions so as to achieve recognition and self-organization along an artificial polymer
involves the most important concepts of supramolecular chemistry and host–guest interactions: balancing and orienting the steric
repulsion, attractive solvent-driven hydrophobic effect, and electrostatic forces. The techniques needed for the controlled folding of
these chemically diverse and intriguing sequences have been honed over the past two decades. The major types of building blocks
and the structural engineering tools will be touched on in the first part of this article.
p0015 Interest in foldamers within supramolecular chemistry is associated with their ability to mimic the molecular recognition
properties of proteins. Moreover, formation of the biomimetic interaction surfaces of foldamers can yield large exposed surface
patches through which the recognition of a protein partner is possible in a high-affinity and specific way. Foldamers are evolution-
free unnatural chemical entities, whichmeans that evolution-based optimization techniques (phage displays or antibody responses
of the adaptive immune system) cannot be utilized to search for and optimize materials that bind to the target molecules. On the
other hand, their structures are modular, and their molecular weights are normally 5–10 times larger than those of small organic
molecules; methods deployed to explore the chemical space of small molecules therefore prove inefficient for this class of
molecules. Possible approaches to tackle this problem will be discussed in the second part of the article.
p0020 Molecular recognition is well beyond the realm of beautifully sculpted chemical entities: it is a fundamental phenomenon in
biological systems that regulate the three-dimensional structures, the functions of proteins, their interactions, biocatalysis, and
signal transduction. A current problem is to establish whether foldamers are able to interact and interfere with the operation of
biopolymers in a controlled manner. The third and largest part of the article is devoted to a comprehensive account of specific
examples where foldameric sequences exhibit molecular recognition phenomena including small-molecule, membrane, DNA, and
protein binders.
s0015 Foldameric Scaffolds and Design Strategies
s0020 Building Blocks and Structures
p0025 Two major groups of foldamers are distinguished on the basis of the chemical structures of the constituent monomers.1 Aromatic
foldamers utilize mostly rigid residues having sp2 carbons in the backbone, whereas in aliphatic foldamers, the hydrogen-bond
pillars are separated by a chain segment of variable length containing sp3 carbons (Fig. 1). The choice of the monomeric scaffold
depends on factors such as the desired overall secondary structure or the synthetic feasibility. The folding and the positioning of the
functional groups that are complementary to the target can be controlled at the monomeric level of the foldamers, which makes
these oligomers well suited for molecular recognition. A wide variety of monomeric units and the design principles of higher
ordered structures have been comprehensively reviewed for aromatic2–5 and for aliphatic foldamers.1,6–9 We provide here a brief
description of the basic principles.
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Fig. 1f0010 Examples of building blocks of aromatic and aliphatic foldamers.
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s0025 Aromatic foldamers
p0030 The most frequently studied aromatic foldamers are based on oligoamide, oligourea, or oligohydrazide scaffolds. The three-
dimensional structure of an aromatic foldamer is controlled by the rigid shape of the building blocks and the local noncovalent
interactions such as hydrogen bonding and local geometric constraints. Long-range interactions including p–p stacking also play a
significant role in the overall folding. The formation of a stable secondary structure requires restriction of the rotation of the bonds
flanking the aromatic ring, which can be achieved by tailored hydrogen-bonding interactions. A diversity of hydrogen-bond
systems are available for aromatic monomers, and a number of building blocks are capable of multiple separate or bifurcated
hydrogen-bond formation within a monomer.3 To address the problem of the poor solubility of these backbones, different side
chains can be attached: nonpolar alkyl chains to improve solubility in less polar organic solvents or ethylene glycols and ionic
groups to enhance solubility in polar or aqueous media. Enhanced solubility coupled with favorable crystallinity has been found to
result from the attachment of isobutyl side chains.10
p0035 Two major secondary structure types can be distinguished among aromatic foldamers: folded helical and extended structures
(Fig. 2A) (for a detailed review, see Ref. 3). The helical radius can be reliably predicted by the choice of the monomer and the
substitution pattern,13 while the handedness of the helix can be controlled by the introduction of chiral monomers.14 The
compounds can generally be characterized by NMR Au2and X-ray crystallography, as they are relatively stable with well-defined
conformations and favorable crystallinity.
s0030 Aliphatic Foldamers
p0040 Aliphatic foldamers can be categorized in terms of the hydrogen-bond pillar functional group present in the backbone. The most
frequently studied aliphatic foldamers contain an amide function. Azapeptides and oligoureas are also promising structures with
improved H-bond donor–acceptor pillars. Peptoids display a side-chain functionality on their amide nitrogen eliminating the
H-bond donor from the backbone (Fig. 1). Homologously to the natural a-amino acid sequences, b-peptides have a backbone
chain extended by one carbon, thereby creating an additional substitution position and stereogenic center. Among the advantages
of such building blocks are the facts that they allow the incorporation of proteogenic side chains and the synthesis of the
homologous amino acids is generally feasible.15 Conformationally constrained monomers with a cycloalkane or heterocyclic
ring can be incorporated so as to preorganize the dihedral constraints in order to achieve a desired secondary structure.16 Peptidic
foldamers constructed for molecular recognition purposes can either be based exclusively on unnatural building blocks or be
prepared as mixed oligomers of a- and b-amino acids designated as a/b-foldamers.8,9,17
p0045 Formation of the secondary structure of b-peptides depends on local conformational preferences and long-range hydrophobic
and hydrogen-bonding interactions; several turns, strands, and helices have been described experimentally.7 The construction of
helices is relatively straightforward; a number of pure b-peptide helices have been identified, such as the 14-helix (Fig. 2B),18 which
is frequently used. The formation of 12-, 10-, 8-, 18-, 10/12-, and 18/20-helices has been observed experimentally for pure
b-peptides,7,19,20 and a/b-peptides with heterogeneous backbones can exhibit more diverse structures.8,9,21 The rational design
of secondary structure can be tuned at the monomeric level through the conformation and stereochemistry of the b-amino acid
units via the methodology known as the “stereochemical patterning” approach.19,21–24
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Fig. 2f0015 (A) Selected secondary structures formed by aliphatic foldamers: a pure b-peptide 14-helix and a mixed a/b-peptide 14/15-helix. (B) Examples
of a helical11 and an extended structure12 of aromatic foldamers.
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p0050 Strand-like structures and turns can be formed,7 but the construction of b-sheet scaffolds is not as straightforward as that of
helices. Design strategies that utilize aa!b2- or b3- or b2,3-residues in hairpins can be utilized to mimic the side-chain structure of
the natural hairpin,25 but in more complex systems, these substitutions are not tolerated.26 Different a!b substitutions in
multistranded antiparallel sheets have furnished promising results,27,28 and macrocyclization can facilitate the preparation of
folded b-sheets.29
p0055 The synthesis of oligomers usually relies on standard peptide synthesis protocols, solid-phase peptide synthesis, or microwave-
assisted syntheses for difficult sequences and foldamer libraries. Inexpensive and effective synthesis can be achieved by means of a
recently reported continuous flow method, which needs only a 1.5 equiv. amino acid excess.30
p0060 Among aliphatic foldamers, peptoids have found a wide range of biomedical applications. The side chains of peptoids are
situated on the nitrogen atom, and they can be regarded as oligomers of N-substituted glycines. This substitution leads to the
absence of hydrogen-bond donor functionality and asymmetry in the backbone. Peptoids are therefore highly flexible. Amide side
chains that restrict the backbone flexibility are able to stabilize different secondary structures: helices, loops, and turn structures.
The secondary structure can be evaluated by using circular dichroism or NMR; in consequence of the flexibility, crystallography is of
limited use. The straightforward and modular synthetic methods allow the incorporation of diverse functionality and the
generation of large libraries. Peptoids therefore serve as attractive scaffolds for biological applications.31,32
s0035 Design Strategies for Molecular Recognition
s0040 Small-molecule recognition
p0065 Helical cavities of aromatic foldamers with matching anchor points inside the cavity can serve as small-molecule receptors. The
modular nature of these foldamers permits fine-tuning of the size of the helix and the arrangement of functional groups that
interact with the guest molecules, which is the basis of their selectivity. Helix folding and recognition can occur simultaneously
during recognition, or preformed structures can be utilized.33 Since a helix can be regarded as a chiral environment, good
stereoselectivity can be achieved through differences in helical handedness, induced by the binding of an enantiomer or by the
attachment of a chiral moiety to the helix. The construction of helices from monomers that promote different helix curvatures
combined with monomers that do not lead to an internal cavity resulted in the design of unimolecular capsules known as
molecular “apple peels.”34 The arrangement of host groups can be refined through a structure-based iterative approach, which
can be a general tool for the construction of highly selective receptors.35
s0045 Recognition of macromolecules
s0050 Structure-based design
p0070 Foldameric designs may rely on a structure-based approach, which requires a knowledge of the structure of the protein interaction
interface. The target surface is normally analyzed in the presence of a peptide epitope or partner protein so as to derive residue and
side-chain positions for the designed foldamer ligand. This strategy is generally used for the construction of protein helix mimetics
by functionalizing an appropriate scaffold with proteogenic side chains. This approach does not allow the entire geometric
arrangement of the original structure to be mimicked, but a similar presentation of the functional groups may result in similar
binding properties. The advantage of this approach is that the side-chain functionality is assumed not to affect the secondary
structure of the scaffold, and it therefore allows the testing of different side-chain patterns with a rigid secondary structure template.
p0075 The 14-helical b-peptide structure has been frequently used for the templating of proteinogenic side chains (Fig. 3A). Its surface
can be segmented into three faces, with the side chains in juxtaposition in parallel with the helix axis. Two faces of the helix can be
designed to enhance structural stability: one face for ion-pairing interactions and another for hydrophobic stacking, a combination
leading to stability and solubility in water.36 The third face of the helix presents the proteogenic side chains toward the protein
interface corresponding to the epitope residues.
p0080 Extended structures of aromatic oligoamides are also capable of mimicking the side-chain presentation of an a-helix with use for
protein recognition.37,38 The stability of linear aromatic foldamer structures makes possible the attachment of proteogenic side
chains that correspond to the i, i+4, and i+7 positions of an a-helix with similar distances between the functional groups.
s0055 Sequence-based design
p0085 Sequence-based design is an alternative strategy that requires the knowledge of a peptidic sequence or segment interacting with the
target, which can be used as reference material.17 The optimization is carried out on the backbone structure, while the side-chain
functionalities generally remain constant. This approach results in foldamers with heterogeneous backbones, which can be further
optimized and stabilized to achieve the desired fit to the target.
p0090 The choice of the substitution patterns in helix mimetic structures often relies on the heptad repeat motif of the a-helix in an
aabaaab backbone pattern (Fig. 3B), which results in the creation of a b-amino acid stripe along one side of the helix. Similarly to
the aabaaab pattern, other repeating units, such as aab or aaab, can adopt helical conformations that closely resemble those of the
original a-helix.39 These substitutions provide increased stability against proteases and possible protection against immune
reactions. It has been shown that immune receptors that recognize a-peptides do not necessarily cross-react with a/b-peptide
analogs.40 There are a number of examples of substitutions with constrained amino acid types that lead to enhanced helical
stability and affinity. Further examples demonstrate that substitutions in contact with the recognition site may alter the selectivity
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toward a different target, and it is not necessary to exclude b-amino acid substitutions from the recognition site.41 In the event of
more complex interaction interfaces, an alanine scan or a b-amino acid scan of a known sequence can aid the selection of residue
positions available for nonnatural amino acid substitutions.
s0060 Fragment- and library-based methods
p0095 The lack of a known peptidic binder or limited structural information on the target surface results in more challenging design
approaches. De novo design or the bottom-up approach for foldameric sequences is particularly difficult, because evolutionary
methods (eg, a phage display) cannot be utilized in the search for new foldameric ligands with nonproteogenic amino acids.
A fragment-based approach is a versatile tool with which to find small-molecule protein ligands42; through the utilization of a short
foldameric segment library as recognition fragments, this design strategy may be extended. After the screening of small oligomeric
fragments for weak binders, the binding affinity can be enhanced by the creation of multivalent ligands as revealed by a few
examples among foldamers.43,44
p0100 Residue-level combinatorial library synthesis combined with high-throughput screening techniques provides an efficient way to
test a large number of compounds. Peptoids are well suitable for library synthesis.32,45 Small libraries have generally been prepared
from previously identified lead b- and a/b-peptides with the goal of testing structural stability or affinity changes due to different
substitutions.46,47
s0065 Foldamers for Small-Molecule Recognition
p0105 Aromatic oligoamide foldamers are well suited for hosting solvent molecules or small guest molecules such as saccharides. The
recognition takes place either in a cavity endowed with a complementary interaction pattern or over a recognition pattern along
the outer surface of the foldamers. Moreover, the helices of the aromatic foldamers can provide a chiral environment, and the
stereoselective encapsulation of guest molecules can therefore be achieved.
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Fig. 3f0020 Summary of the design strategies utilized for macromolecule recognition by using foldamers. (A) Structure-based design by mimicry of a known
side-chain presentation of a helical structure by a b-peptide helix or a linear aromatic scaffold. The epitope residues are highlighted in green.
(B) Sequence-based design with different substitution patterns for helices or an alanine or b-amino acid scan for more complex structures. b-Amino
acids are colored light blue. (C) Enhancement of affinity by a multivalent ligand based on a helical foldameric fragment. (D) Combinatorial library
approach.
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s0070 Encapsulation of Solvent and Small Polar Guest Molecules
p0110 Helical aromatic foldamer receptors have gained applications as hosts for solvent or small molecules. The position of hydrogen-
bond donors and acceptors can be designed that is appropriate for the achievement of the complementary recognition of small
solvent and polar molecules. On binding to cyanuric acid, a linear oligo(isophthalamide) that consisted of donor–acceptor–donor
units underwent a conformational change to helix.48 Intermolecular hydrogen-bonding and p-stacking interactions in the host–
guest complex governed a further self-assembly into columnar structures at high concentrations. A further example is a simple,
crescent-shaped oligoamide foldamer host, designed to have the number and distribution of hydrogen-bonding sites facilitating
the recognition of the guanidinium ion, the complementarity of which resulted in high binding selectivity.49
p0115 Short pyridine-based oligoamide foldamers have been reported to bind water molecules and have been denoted as aquafolda-
mers. The entrapment of an unconventional water dimer by a planar trimeric foldamer proved to be based on the interaction
between the hydrogens of water (HdH) rather than the conventional hydrogen bond (OdH). Longer, helical-shaped foldamers
were able to accommodate two water molecules through the involvement of conventional hydrogen bonding with different
strengths.50,51
s0075 Molecular apple peels
p0120 Control over the internal diameter along a single helix has been achieved by combining monomers with different local shapes. The
helix diameter was controlled so as to be large at the center and narrow at the termini, resembling an apple peel.34 The center of the
helix consisted of three pyridine units alternating 2,6-diaminopyridine and 2,6-diaminopyridinecarboxylic acid capped with two
8-amino-2-quinolinecarboxylic acid units (Fig. 4A). Modeling studies revealed that the pyridine units provide a large polar cavity,
suitable for small polar guest molecules, while the quinoline units at the end of the sequence close the helix.
p0125 X-ray crystallography and later NMR measurements demonstrated that the foldamer was able to host a water molecule with a
binding constant of 150 M1 in chloroform. Longer oligomers with an increased number of pyridine units in the center exhibited
methanol binding, stoichiometry depending on the oligomer length. Other guest molecules, such as hydrazine, hydrogen peroxide,
and formic acid, were also able to bind to these aromatic oligoamides.52
p0130 Molecular dynamics studies on pyridine–quinoline apple peels revealed that the conformational changes that occur upon
ligand release are more pronounced in the central hollow of the helix. Two types of release mechanisms were identified: (i) ligand
release along the helix axis, from the “top,” and (ii) side opening. The release mechanism depended on the ligand, the binding site,
and the solvent. Small ligands (such as water) tend to escape from the top.55
p0135 Further expansion was achieved by constructing a larger helix with five different aromatic monomers that contained one, two, or
three fused aromatic rings, governing the cavity size for the selection of appropriate guest molecules. Several different alkanediols
and unsaturated diols were able to bind, with Ka values of 500–5000 M
1 (Fig. 4B).53
p0140 Helices can provide an asymmetrical environment as a result of their specific chiral information, and they are therefore useful
for stereoselective recognition. It has been shown that the L-tartaric acid enantiomers may be encapsulated by a helix with unique
handedness. The selectivity is based on the matching interactions between the hydroxy groups of the tartaric acid and the inner
cavity of the appropriate helix; L-tartaric acid is bound by the M-helix and D-tartaric acid by the P-helix.54 Control of the helix
handedness was achieved by introducing chiral camphanyl moieties into the foldamer.56 Diastereoselectivity occurs during the
release of the guest: binding kinetics investigations have revealed that the inner core is responsible for the selectivity. Furthermore,
longer and more stable helices resulted in more frequent opening of the helix, which did not decrease the guest binding and release
rates.57 Helices with opposite handedness were connected with the aid of a terephthalamide central moiety (Fig. 4C), where the
Comp. by: MSanthiya Stage: Proof Chapter No.: 12547 Title Name: SMC2
Date:25/6/16 Time:06:54:20 Page Number: 6
Fig. 4f0025 (A) Molecular apple peel structure consisting of pyridine and quinolone units.52 (B) X-ray structures of molecular apple peels encapsulating
water dimers52 and 1,4-butanediol.53 (C) Crystal structure of connected P- andM-helices encapsulating D- and L-tartaric acid, respectively.54 The central
terephthalamide moiety is highlighted in blue. Hydrogen atoms and isobutyl side chains have been removed for the sake of clarity. Crystal
structures were obtained from: Experimental Crystal Structure Determination; Cambridge Crystallographic Data Centre, https://summary.ccdc.cam.ac.
uk/structure-summary-form CCDC 645198, 677155, and 945577.
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hydrogen-bonding motif of this central monomer promotes opposite handedness on the two sides.58 This approach additionally
proved that quasi-racemic crystallography is advantageous in the case of aromatic foldamers.
p0145 The in situ modification of the backbone of these aromatic oligoamide helices is feasible to control the structure and binding
affinity. In situ reduction of the pyridazine unit to pyrrole resulted in helix contraction and release of the guest molecule.
In response to ring contraction, the affinity toward tartaric acid decreased by two orders of magnitude upon ring contraction.59
Molecular apple peels were used to generate capsules for saccharide moieties, as described in the following section.
s0080 Encapsulation of Saccharides
p0150 The selective recognition of saccharides is a challenge in view of the existence of their structurally close, naturally occurring analogs.
Different isomers of monosaccharides can coexist in solution; the difficulty of designing a selective and high-affinity receptor is
increased by the mutarotation of glucose and the tautomeric furanose and pyranose forms. A further challenge is the occurrence of
competing hydrogen bonds between a polar solvent and a saccharide molecule, which decreases the chance of high-affinity
binding. A number of aromatic foldameric scaffolds have been employed to address monosaccharide recognition (Fig. 5) by
applying helices with a hydrophilic internal cavity capable of participating in multiple hydrogen bonds.33
p0155 Oligobenzamide foldamers with crescent and helical conformations have been shown to bind different triol and saccharide
compounds in chloroform. Structural investigations revealed that all the carboxyl groups pointed inward, producing a cavity
capable of the formation of multiple hydrogen bonds with a diameter of 0.9 and 0.8 nm for the pentamer and heptamer foldamers,
respectively. The association constants were estimated in the range of 550–7800102 M1.11
p0160 The selective molecular recognition of alkyl saccharides was achieved by oligohydrazide foldamers in chloroform.60 Molecular
mechanics calculations indicated that the rigid cavity of these oligomers was in the range of 10.6–11.1 A˚, and the interior of
the cavity was filled with carbonyl groups acting as hydrogen-bond acceptors. The binding strength was length-dependent, and the
binding constant of a tridecamer to maltose was 7106M1. Chirality was introduced into the hydrazide foldamers through the
incorporation of R- or S-proline, which resulted in controlled helicity of the foldamers with good diastereomeric selectivity toward
glucoses in chloroform.61
p0165 Another approach utilized poly- and oligo(m-ethynylpyridine) foldamers, which folded into helices upon the addition of
saccharides. The association constants for hexoses were of the order of 103 M1.62 The functionalization of the m-ethynylpyridine
units with dialkylamino groups resulted in pH-dependent saccharide binding. The affinity could be enhanced by the addition of up
to 0.5 equiv. of acid relative to the pyridine ring.63 The pyridine–ethynylene scaffold was further expanded to create pyridine–
pyridone co-oligomers. In the absence of the guest molecule, the foldamer self-dimerized, while after the addition of octyl
b-D-glucopyranoside, the oligomer dissociated and bound to the saccharide.64
p0170 An iterative design approach for the selective encapsulation of a selected monosaccharide was developed, which can be applied
as a general protocol for the construction of highly selective receptors.35 The design strategy was begun with the construction of a
first-generation oligomer from a monomer library (Fig. 6A), where the inner cavity is filled with hydrogen-bond donors and
acceptors, but the spatial arrangement has not yet been targeted to a specific guest molecule. The crystallographic data on the host–
guest complexes were utilized to achieve an iterative amplification of affinity so as to generate a more selective host toward fructose
(Fig. 6B), by retaining the favorable interactions with the selected guest and sterically excluding all other guest molecules. This was
accomplished by the mutation, deletion, or addition of specific aromatic monomers in the starting receptor, which was made
possible by the modular structure of these types of foldamers. The iterative design led to increased affinity toward fructose
(Ka¼30,500 M1) and decreased affinity to other monosaccharides (Ka<240 M1).
s0085 Hydrophobic Molecule Recognition and Ion Receptors
p0175 During the solvophobically driven folding of m-phenylene ethylene (mPE) oligomers, a tubular hydrophobic cavity is formed.
Various terpenes with complementary size and shape have been demonstrated to bind, with association constants of the order of
103 M165 and 104–106 M1 for the water-soluble mPE oligomer modified with ethylene glycol side chains.66 An increase in the
chain length of the mPE oligomer resulted in the binding of a rodlike piperazine derivative molecule.67 The binding affinities
proved to be dependent on the oligomer length, the association constant increasing from the dodecamer to the octadecamer.
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Fig. 5f0030 Building blocks of foldamers for saccharide recognition: (A) oligobenzamide,11 (B) isophthalimide–hydrazide,60,61 (C) pyridine–ethynylene,62,63
(D) pyridine–pyridone.64
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The bindingmechanism is presumed to be dynamic, with some deformation of the preformed fully folded helix, resulting in helical
winding around the guest molecule.68 Through the introduction of a hydrogen-bonding capability via the use of an amide
functionality in the backbone of the mPE oligomers, selectivity toward the protonated form of the guest molecule could be
achieved.69
p0180 The outer surface of foldameric templates with special functionalization can also make use of molecular recognition. Aromatic
oligoamides with bisporphyrin moieties were utilized to develop tweezer receptors. The parallel attachment of the porphyrin units
resulted in the ability to recognize fullerenes or 1:1 complexes with planar electron-deficient molecules through stacking by the
porphyrin units.70,71 A helically folded oligoamide foldameric scaffold functionalized with six porphyrin side chains resulted in a
quasi-average spatial distribution of the porphyrin rings; as an example, a matching C60 ligand formed a 1:6 complex with the
receptor.72
p0185 Foldamers capable of electronic interactions and hydrogen bonding are able to serve as receptors for ions, and the folding of the
receptor can occur simultaneously with the coordination to the ion; for a detailed review, see Ref. 33. A large number of acyclic
aromatic foldamers and cyclic oligomers have been shown to serve as anion receptors, as reviewed elsewhere.73 b-Peptide bundles
have been recently shown to coordinate Cd2+, two of them binding to the helix bundle with positive allostery, resulted in increased
thermodynamic stability.74
s0090 Membrane-Interacting Foldamers
p0190 Membrane-interacting compounds can affect numerous biological processes; they can act as antimicrobial agents by disrupting the
membrane or mediate cell penetration. A foldamer with the ability to differentiate between pathogenic and eukaryotic membranes
could possibly be utilized to obtain selective compounds against various pathogens, which could be applied as a new therapeutic
strategy against resistant microorganisms. Interactions with membranes mostly rely on the amphiphilic character of a peptide. The
positively charged side chains are attracted to negative phospholipids, and the spatial separation of the lipophilic amino acids is
also a key feature for antibacterial activity. This design is preferred by evolution; a number of naturally occurring host-defense or
antimicrobial peptides having this structural arrangement have been described.75 The rational design of nonnatural antibacterial
oligomers also follows these principles.
s0095 Peptide Foldamers Against Pathogens
p0195 A crucial property of a potent antimicrobial peptide with low toxicity is its ability to differentiate between pathogenic and eukaryotic
cell membranes. Peptides containing the b3-hVal/hLeu-b3-hLys-b3-hLeu motif demonstrated antibacterial activity in the low
micromolar range, but this was accompanied by high hemolytic activity.76 The specificity was enhanced by lowering the lipophilic
character of the peptides through the incorporation of b3-hAla instead of b3-hVal or b3-hLeu.77 Selectivity toward a bacterial
membrane with low hemolytic activity was achieved by using a/b-peptide 12-helical structures with the conformationally con-
strained residues of (3R,4S)-trans-4-aminopyrrolidine-3-carboxylic acid and (R,R)-trans-2-aminocyclopentanecarboxylic acid.78
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Fig. 6f0035 (A) The aromatic building block library used for the iterative design of saccharide-binding apple peel foldamers and (B) the crystal structure
highlighting the key residues of the optimized oligomer, encapsulating b-2C5-D-fructopyranose. Crystal structure information was obtained from
Ref. 35. Further residues have been removed for the purpose of clarity.
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p0200 An analysis of antimicrobial peptides indicated that activity and selectivity are dependent on the balance between lipophilicity,
charge distribution, and structural flexibility. The net charge of the peptides was shown to be important; the negatively charged
C-terminal carboxylate decreased the activity relative to that of the C-terminal amide analogs.79 The screening of a number of
antimicrobial b-peptides revealed that the limit of MIC Au3was around 1 mg mL1, similarly as found for a-peptides.80
p0205 Previous efforts to design antimicrobial foldamers relied on the construction of globally amphiphilic structures, but these need
not necessarily be in the form of a regular and rigid secondary structure.81 This was shown by using a/b-peptide sequences with an
overall amphiphilic structure in the 11-helical (compound 1) or 14/15-helical (compound 2) conformation and a scrambled
foldamer (compound 3) (Fig. 7). All these peptides displayed antimicrobial activity with varying selectivities. It was concluded that
a backbone with sufficient flexibility that allows the adoption of an amphiphilic conformation in response to a membrane
interaction is sufficient for antimicrobial activity; this is supported by the fact that the scrambled rigid structures did not exhibit
any activity.79 Lipophilicity was not correlated with antibacterial activity, but a reasonable correlation was found with hemolysis:
the higher hydrophobicity of the foldamers induced hemolysis at lower concentrations.
p0210 The selectivity toward different pathogens is based on the membrane lipid composition of the bacteria, and the rational design
of selective foldamers targeted to a specific species may depend on the recognition of the different lipid compositions of bacterial
membranes. Fluorescence and differential scanning calorimetric experiments on different lipid vesicles revealed that the scrambled
peptide induces phase segregation of the anionic and zwitterionic lipids, which results in membrane defects. The reason for this
selectivity may possibly be that this peptide has two clusters of sequentially close cationic residues, which may explain the higher
toxicity to microorganisms in which the membrane is enriched in phosphatidylethanolamine.82,83
p0215 Foldameric sequences have been demonstrated to display activity against fungi. 14-Helical amphiphilic structures have
antifungal activity in the micromolar range.84 The specificity and antifungal activity against Candida albicans and hemolysis
depended on the hydrophobicity and the helix-forming propensity.85 Intermediate levels of hydrophobicity and more stable
helical structures led to higher selectivity. Antiviral applications are also possible among b-peptides. Arginine-rich amphiphilic
b-peptides proved to inhibit herpes simplex virus type I infection.86 Such examples illustrate that b-peptides may be useful
antibacterial, antifungal, and antiviral agents thanks to their designed selectivity toward different membrane compositions together
with increased stability against proteolysis.
s0100 Antimicrobial Arylamide Foldamers
p0220 The amphiphilic nature of antimicrobial peptides can be mimicked by short arylamide foldamers, which have shown good efficacy
and broad-spectrum antimicrobial activity with high selectivity for bacteria over eukaryotic cells. Resistance to this class of
compounds, tested by using procedures applied to other compounds with the use of Staphylococcus aureus, did not develop.87
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Fig. 7f0040 Schematic representation of three a/b-foldameric helices with designed global amphiphilicity81 in the 11-helical (A) or 14/15-helical (B)
conformation or the scrambled sequence (C). Positively charged residues are highlighted in red. ACPC, (S,S)-aminocyclopentanecarboxylic acid; APC,
(3R,4S)-trans-4-aminopyrrolidine-3-carboxylic acid (R,S)-aminopyrrolidine-carboxylic acid (R,R)-trans-2-aminocyclopentanecarboxylic acid.
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p0225 The major component of the mechanism of action of arylamides has been shown to be membrane damage, and arylamide
foldamers can cause rapid disruption of the outer membrane and also low-level changes to the inner membrane of E. coli. Increased
permeability to small ions was observed in the inner membrane, resulting in protein translocation defects and thereby contributing
to the activity. The membrane permeabilization action of arylamides is less extensive than that of natural antimicrobial peptides,
which is likely to be associated with a lower risk of inflammatory responses.88
p0230 Optimization resulted in a lead compound brilacidin (compound 4, PMX-30063; Fig. 8), which is a short arylamide sequence
stabilized by intramolecular hydrogen bonds and substituted by small cationic and hydrophobic groups. In phase 2 clinical trials
for the treatment of bacterial skin infections caused by drug-resistant S. aureus, brilacidin demonstrated good efficacy comparable
with that of the currently used daptomycin (ClinicalTrials.gov, NCT01211470). Brilacidin dose-dependently depolarizes the
S. aureus membrane and induces major stress regulons involved in cell wall and membrane stress.89
s0105 Foldamers for Cell Penetration
p0235 Membrane recognition can lead to the intracellular delivery of potent cell-penetrating peptides without disruption of the
membrane. b3-hArg oligomer hepta- and hexamers90 and short cationic b-peptides analogous to the HIV transactivator of the
transcription protein (Tat)91 displayed cell-penetrating activity and the ability to carry small covalently bound fluorescein
molecules into the cells. The cell-penetration mechanism depended on the sequence and conformation of the peptide and the
cell type. b3-hArg oligomers are transported via a nonendocytic mechanism.90,92 The biphasic mechanism of penetration of these
peptides involves a rapid nonspecific interaction and stronger nonelectrostatic interactions and membrane disruption.93
Tat-derived b-peptides entered HeLa cells through endocytosis.94 It was also demonstrated that penetration can be enhanced by
a stable helical structure that exposes arginine residues on one side, which can be useful in the design of foldamers that have
intracellular targets.95
s0110 Recognition of Nucleic Acids
p0240 The selective recognition of DNA and RNA sequences can inhibit gene transcription with a potential therapeutic outcome. Upon
binding to the major groove of DNA, a number of DNA-recognizing peptides fold into an ordered secondary structure.96 The most
common structure involves a-helix motifs with a recognition pattern through hydrogen bonds between the nucleobases and the
peptide side chains. The sequence-independent recognition of DNA is achieved through ionic interactions with the phosphate
groups found in the DNA backbone. The ordered structure of proteins can lead to the selective recognition of DNA sequences; such
structures include the zinc-finger, the leucine-zipper, and the helix-turn-helix motif.97 Foldameric structures have been designed on
the basis of these observations.
s0115 DNA-Binding b-Peptides
p0245 The 14-helix scaffold has been utilized to design DNA-binding foldamers. Hydrogen-bonding recognition sites were provided by
b3-hAsn and b3-hLys side chains for ionic interactions, and hydrophobic side chains were utilized to provide the helix with an
amphipathic character.98 The helix does not have its own secondary structure because of the repulsive interaction between the
positively charged side chains, but upon the addition of DNA, the CD Au4curve resembled that of a 14-helical structure. Both single-
and double-stranded DNAs were shown to interact with the foldameric helix.
p0250 A number of analogous peptides have been designed and CD titration experiments were carried out with DNA. Two
pentadecapeptides and b-octaarginine underwent significant interaction with the dA20dT20 DNA duplex.
99 A number of these
foldamers (5; Fig. 9) displayed affinity toward a functional DNA sequence, which is involved in cyclic AMP regulation.
Comp. by: MSanthiya Stage: Proof Chapter No.: 12547 Title Name: SMC2
Date:25/6/16 Time:06:54:24 Page Number: 10
Fig. 8f0045 Structure of brilacidin.89
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s0120 DNA Recognition by Oligoamide Foldamers
p0255 Helical trimeric or tetrameric oligoamides of quinoline have been demonstrated to bind to DNA G-quadruplex structures, which
are supramolecular structures of guanine-rich sequences.102 G-quadruplexes can be found in promoter regions and telomeres,
suggesting their important role in the control of gene expression and telomere maintenance.103,104
p0260 The search for foldamer–G-quadruplex interactions was carried out on the DNA side, which was optimized to bind to octamers
of quinoline oligoamides through the use of systematic evolution of ligands by exponential enrichment. This method has been
utilized to optimize DNA aptamers for a wide range of targets.105 Specific binding to G-quadruplexes with an estimated
submicromolar affinity was observed through SPR measurements.106 The interactions between quinoline oligomers and
G-quadruplex DNA could be made diastereoselective by tuning of the helix handedness. This was achieved by introducing a chiral
camphanyl group into the foldamer, which controls the handedness of the helix.56 Almost all aptamers proved to lose affinity after
this modification; the one exception exhibited selectivity toward the M-helix. Tests of DNA versus RNA selectivity revealed that the
foldamer is selective toward the DNA G-quadruplexes and does not interact with RNA.
p0265 Further optimization of the oligoamide foldameric molecules was carried out by generating a library of small helices and
macrocycles. FRET Au5melting experiments revealed the ability of the foldamers to interact with a variety of G-quadruplex structures.100
Cationic side chains and the foldamer length played important roles in the stabilization, with an octamer as the most potent
compound (structure 6; Fig. 9).
s0125 Foldamers for Gene Delivery
p0270 Cell-penetrating peptides with pH-responsive residues offer favorable applications among nonviral transport systems for nucleic
acid delivery accompanied by increased endosomal escape.107 An effective pH-responsive oligourea foldamer has been developed
by thiol-mediated dimerization of a short 8-mer amphiphilic oligourea sequence (compound 7; Fig. 9) and employed as a
transfection agent.101 The transfection efficiency of the foldamer, without addition of helper lipid or Zn2+, was comparable with
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Fig. 9f0050 (A) Structure of the G-quadruplex-stabilizing oligoamide foldamer helix.100 (B) DNA-binding b-peptide sequence.99 (C) Sequence of the
pH-responsive oligourea foldamer for gene delivery.101
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that of LAH4, an efficient His-rich cell-penetrating peptide. Selective inhibition of the acidification of endosomes diminished the
activity by 13-fold, highlighting that the protonation of imidazole groups is required for activity.
p0275 Peptoids have been confirmed to interact with plasmid DNA, with a potential application as a gene delivery system, through the
binding of the DNAwith basic side chains and hydrophobic residues, facilitating cell entry. The repeating triplet of cationic and two
hydrophobic residues successfully crossed the cell membrane, with localization to the nucleus. A 36-mer peptoid, identified by a
combinatorial method, displayed transfection efficacy similar to that of the standard lipofection method.108
s0130 Foldamers Against RNA
p0280 Protein–RNA interactions are involved in various biological processes, such as transcription or translation. The ability to influence
these interactions would provide tools for molecular biology or medicine. The challenges of RNA recognition lie in the structural
diversity of the RNA molecule, which can fold into complex tertiary structures consisting of loops, turns, and bulges playing
important roles in protein–RNA interactions.97 A routine design of general RNA recognition molecules is therefore impossible.
p0285 Themost frequently studied RNA is the transcriptional activator-responsive element (TAR) RNA, which is involved in regulation
of the gene expression of the virus HIV-1.109 The transcription of HIV RNA requires the interaction between the Tat protein of the
virus and the TAR RNA, which is a bulged RNA hairpin structure. A number of peptoids have been designed to target the TAR RNA
on the basis of the sequence of the arginine-rich region of the Tat protein, with similar affinities to those of the Tat. FRET
experiments resulted in high-affinity complex formation, with a KD of 68 nM for the most potent peptoid, an ester derivative.
110
p0290 An oligourea foldamer was designed by direct sequence conversion of the arginine-rich region of the Tat protein that displayed a
KD of 111 nM, and specificity toward TAR RNA was demonstrated.
111 Similar results were obtained with a carbamate derivative,
which was shown to bind specifically to the characteristic trinucleotide bulge of TAR RNA.112
p0295 An 11-residue b3-peptide was also designed against TAR RNA, based on the sequence of the Tat protein, and yielded nanomolar
affinity (KD¼29 nM).113
s0135 Foldamers for Protein Recognition
s0140 Recognition Through a Helical Interface
p0300 A number of protein–protein interactions are mediated by an isolated a-helical secondary structure, in this case, a helical protein
segment fitting into a binding cleft. These interfaces are frequently targeted with foldamers, because the design strategies for
foldameric helices or structural mimetics are well established, and various unnatural scaffolds are available. The successes of the
foldamers in this field highlight their ability to accommodate the structural requirements of helix-mediated protein–protein
interactions.
s0145 Inhibition of p53–hDM2 interaction
p0305 p53 is one of the highly mutated genes that have been identified in human cancerous diseases. Inhibition or malfunction of the
protein can lead to tumor development, and stimulating p53 activity can lead to tumor suppression. In certain cancer types, hDM2
(human oncogene product double minute 2), a negative regulator of p53, is highly expressed. Inhibition of the interaction between
p53 and hDM2 leads to the p53-mediated apoptosis of tumor cells.114 The molecular mechanism of the interaction between the
two proteins has been well characterized: hDM2 recognizes a short helical motif of the p53 activation domain (p53AD). The
hydrophobic face of the helix contains three hot-spot residues, Phe19, Trp23, and Leu26, which contribute the bulk of the binding
energy.115–118
s0150 Structure-based b-peptide helix mimetic design
p0310 A structure-based b-peptide design strategy has been utilized with the goal of achieving a similar side-chain presentation as that of
the original a-helix motif. The b-peptide 14-helix scaffold was chosen, which allows side-chain presentation on one side of the
helix, though the overall structure is not consistent with the a-helix.119 One face of the 14-helix contained b3-amino acid analogs of
the hot-spot residues (epitope face; Fig. 10); the other two faces of the helix contributed to structural stability and solubility in
water. The stability of the 14-helix was achieved through side-chain–side-chain salt bridges on one face of the peptide together with
stabilization of the macrodipole of the helix.36 Fluorescent polarization assays demonstrated that the most potent peptide
(compound 8) exhibited a KD of 368 nM, which was only 1.6-fold lower than the affinity of p53AD15–31 for hDM2.
119 A b3-
hAla scan of the key residues revealed that all three residues are involved in and important for the interaction with hDM2, and their
arrangement is crucial.
p0315 A further improvement of the activity was achieved by a one-bead one-compound library approach.46 The library screen was not
affected by the epitope mimetic side-chain presentation, but only by the overall structure and helix-forming propensity of the
foldamer. Analogs were synthesized on TentaGel macrobeads and analyzed by a fluorescence-based method to permit manual
selection of the active compounds. Improved activity and higher helical content were observed for analogs in which b3-hVal was
replaced by b3-hIle (peptide 9), this being a proved approach to enhance the helical fold.120 Use of the nonnatural
3-trifluoromethylphenyl side chain increased the affinity 10-fold (peptide 10; Kd¼28.2 nM) and led to binding with submicromolar
activity to hDMX, another key protein in activation of the p53 pathway.121
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p0320 The p53–hDM2 interaction takes place intracellularly and the foldamer must therefore penetrate the cell wall. A general
approach for the increase of penetration is to introduce a polyarginine tag, but this can increase toxicity122 and lower the stability
against proteolysis. The most successful strategy for maintenance of the 14-helical fold and the affinity for hDM2 involves
substitution with b3-hArg residues in the salt-bridge face of the peptide (peptide 11).123 Cell uptake is enhanced by introducing
a diether or hydrocarbon bridge as a “staple” at positions i and i+3 in one face of the peptide. The bridge between positions 4 and
7 resulted in twofold higher affinity toward hDM2 and more efficient uptake, which correlated with the hDM2 affinity in vitro.124
s0155 Oligoamide foldamers for hDM2 inhibition
p0325 An oligoamide foldameric scaffold was built to reproduce the appropriate side-chain projection of the recognition epitope without
the need to mimic the overall folding geometry of an a-helix. Rodlike oligobenzamide foldamers with O-alkyl substituents as side
chains resulted in low micromolar inhibitors of the p53–hDM2 interaction.125
p0330 An a-amino acid-containing hybrid foldamer was constructed that allowed access to multiple conformers that present the
pharmacophore side chains in diverse orientations.37 The side-chain composition and the spacing between the monomeric units
were shown to play key roles in protein recognition and tuning selectivity. The stereochemistry of the central monomer was
responsible for selectivity toward the p53–hDM2 or Mcl-1–NOXA-B interaction (compounds 12 and 13; Fig. 11A). Both
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Fig. 10f0055 Sequence evolution of b-peptide 14-helix foldamers for hDM2 inhibition. The three faces of the 14-helix indicated by different
colors, which involve residue changes relative to the previous foldamers, are underlined. KD values were measured by direct fluorescent polarization
assays and IC50 values for inhibition of the p53AD–hDM2 interaction by competitive fluorescent assays. Data are from Harker, E.A.; Daniels, D.S.;
Guarracino, D.A., Schepartz, A. b-Peptides With Improved Affinity for hDM2 and hDMX. Bioorg. Med. Chem. 2009, 17(5), 2038–2046; Harker, E.A.;
Schepartz, A. Cell-Permeable b-Peptide Inhibitors of p53/hDM2 Complexation. ChemBioChem 2009, 10(6), 990–993.
Fig. 11f0060 (A) Structure of the hybrid oligoamide foldamer. IC50 values were measured by fluorescent competitive assay.
37 (B) Structure of the most
potent peptoid for inhibition of p53–hDM2 interaction.126 The pharmacophore side chains are indicated with gray shadings.
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enantiomers exerted inhibitory activity against the p53–hDM2 interaction, but only the oligomer that contained the (R)-Phe
variant demonstrated activity as concerns the Mcl-1–NOXA-B interaction. This was the first example of a foldamer that exhibited
different selectivities through the alteration of only one stereogenic center.
s0160 Peptoids for the hDM2–p53 interaction
p0335 A peptoid ligand was designed to mimic the appropriate orientation of the key residues structurally.126 The simple transposition of
the sequence to a peptoid helix results in misalignment of the three key residues (Phe19, Trp23, and Leu26); this was corrected by
deleting one position from the sequence. The orientations of the projected side chains are at different angles; this was adjusted by
the addition of one methylene group to both the phenylalanine and the tryptophan side chains, which allows greater flexibility.
Increased solubility in water was achieved by introducing phosphonate side chains, which led to a destabilized helix and weak
binding to hDM2. The binding affinity was increased by introducing other synthetic modifications of the side chains, for example,
substituting p-nitro groups in one of the phenylethyl side chains and chlorine at position 6 of the indole ring of tryptophan
(compound 14; Fig. 11B). Removal of chirality also resulted in increased activity, though it demolished the helical fold. It is
hypothesized that the helix conformation of the peptoid is adopted upon binding to hDM2. As concerns the epitope moieties, the
binding affinity is decreased markedly when the phenylalanine side chain is lost, but less dramatically than observed in other
hDM2-binding peptides.
s0165 Inhibitors for B-cell lymphoma 2 (Bcl-2) protein family members
p0340 Apoptotic events are regulated by a number of pro- and antiapoptotic proteins and are potential pharmaceutical targets in cancer.
The Bcl-2 protein family plays a key role in the regulation of apoptosis. The antiapoptotic proteins of this family (including Bcl-2,
Bcl-xL, and Mcl-1) are regulated through interaction with the Bcl-2 homology 3 (BH3) domain of proapoptotic proteins, such as
Bak, Bim, or PUMA Au6. The activation of antiapoptotic cellular processes is observed in cancer, which enables cancer cells to survive
and decreases the effectiveness of chemotherapy, and the inhibition of this interaction may therefore be advantageous in the
therapy of cancer diseases. Short peptidic sequences derived from the BH3 domain of Bak efficiently suppressed the antiapoptotic
defense by binding to Bcl-2 family proteins.127 The interactions of the antiapoptotic proteins with the BH3 domain of proapoptotic
proteins proved to be a good model system for the design of helix mimetic foldamers with different scaffolds.
s0170 Structure-based design of a b-peptide foldamer
p0345 The b-peptidic foldamer helices are well suited for mimicking the Bak–Bcl-xL interface. The interaction site involves a 16-mer
helical segment on the BH3 domain of Bak, which is recognized by the hydrophobic groove on Bcl-xL. The interaction interface
contains residues in the helical segment of BH3 in contact with the target protein, most of these residues being hydrophobic (Val74,
Leu78, Ile81, and Ile84). The importance of hydrophobic interactions has been clearly proved by alanine scan experiments.128
p0350 The initial approach was to redesign the a-helical segment with pure b-peptidic scaffolds, such as the 12- or 14-helix.129 The
precise geometric requirements of the a-helix were not achieved by these scaffolds, and the design approach was unsuccessful: only
weak interactions were observed, with IC50>500 mM.
p0355 In the next step, mixed a/b-peptide scaffolds were used, that is, the 11- and the 14/15-helices, which can be stabilized by
utilizing five-membered ring-constrained amino acids. The designed peptide resembled closely the a-helix, but was less potent,
with a Ki of 1.5 mM as compared with the Ki of 0.025 mM for the 16-mer Bak peptide. The reason for the reduced affinity was
presumably the local mismatch of the helical scaffold at the recognition site. In the next step, therefore, chimera peptides (a+a/b)
were designed in which the pure a-amino acid sequence was kept in the C- or N-termini and the side-chain chemistry of the original
Bak peptide was retained. Two patterns were tested, which resulted in highly different affinities: IC50¼0.059 mM for the (ba)5a5
(compound 16; Fig. 12A) and IC50>700 mM for the a8(ba)4 pattern, which highlighted the importance of the C-terminal sequence
in binding. NMR measurements of an analogous peptide confirmed the 14/15-helix formation in the a/b-peptide region and
suggested a-helix induction in the pure a-peptidic sequence. Sequence–affinity relationships were established via alanine and
hydrophile scans, which were further rationalized by the computational model of Bcl-xL and the foldamer sequence.132 The potent
sequences demonstrated apoptotic activity by inducing cytochrome c release from the mitochondria.
p0360 Further structural characterization was carried out by using X-ray crystallography, and it was concluded that the chimera
foldamer was able to mimic the a-helical arrangement effectively.130 The bulk of the BH3 domain of Bak peptide could be replaced
by an a/b-peptide scaffold, but the sensitive C-terminal part was still susceptible to proteolysis. In order to improve the resistance to
proteolysis, systematic amino acid substitutions were carried out in the a-peptidic part. A combinatorial library approach was used
to screen the 6 residues in the a-helix for possible substitutions. Single a!b substitutions resulted in lower affinity for Bcl-xL,
which was explained by the misalignment of the interacting side chains due to the extra carbon atom in the backbone.
An additional library screen was conducted with several different types of substitutions, a!a, a!b, and a!null residues,
including the use of constrained amino acid types. A few of the library members displayed activity, but the original sequence
remained the most potent. Improvement of the resistance against proteolysis was achieved through one or two substitutions with
nonnatural a-amino acid and/or b3-amino acid residues,47 while a similar affinity to that of the 16-residue Bak peptide was
observed.
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s0175 Sequence-based a/b-foldamer design
p0365 The sequence-based design approach relies on the replacement of regularly spaced a-residues with b-residues retaining the original
side-chain chemistry, which introduces an extra carbon into the backbone. The location of the replacement is based on the heptad
repeat principle, which defines faces running along one side of the helix. Nonnatural monomers are presented at one face of the
helix, and it is possible for them to make minimal contact with the protein surface. A number of b3-amino acid mutations were
carried out in an aabaaab pattern for the Puma BH3 domain, which resulted in high-affinity foldamers.133 The most potent
foldamer with increased stability against proteases had KD¼2.2 nM toward Bcl-xL and KD¼110 nM toward Mcl-1, another
member of the Bcl-2 protein family. The location of the b-residues strongly influenced the selectivity and affinity for the protein
targets. Structural investigation of the foldamers revealed low helical propensity, and they were thought to fold into a helix only
upon binding to the partner protein. The success of this approach suggested that sequence-based design is more efficient than a
structure-based approach.
p0370 For confirmation of the widespread application of the sequence-based design approach, substitutions were carried out in
different possible patterns in the BH3 domain of Bim protein: aabaaab, aab, and aaab (Fig. 12).131 Analysis of the strong binders
revealed that it is not necessary to isolate the b-amino acid residues from regions away from the binding site. Compound 19 proved
to mimic the binding effectively with increased proteolytic stability, even though it involved less than 30% of amino acid
replacements.
p0375 The aabaaab and aaab analogs of the 18-mer Bim BH3 domain were subjected to b3!cyclic b-amino acid replacements
(compounds 18, 20, and 21), utilizing a five-membered ring-constrained amino acid with an acidic side chain, which allowed the
replacement of acidic amino acids.41 These mutations in positions not in direct contact with the protein exerted modest effects on
the affinity for Bcl-xL or Mcl-1. In the aaab pattern, constrained residues in positions in contact with the recognition site (peptides
Comp. by: MSanthiya Stage: Proof Chapter No.: 12547 Title Name: SMC2
Date:25/6/16 Time:06:54:27 Page Number: 15
Fig. 12f0065 (A) Sequences and affinities of the a/b+a-, aabaaab-, and aaab-foldamers based on the Bak and Bim BH3 domain. a-Amino acids
are indicated with single-letter codes, Ki values are derived from competitive FP assays.
41,129 (B) Crystal structure of the chimera a/b+a-ligand with
Bcl-XL (PDB 3FDM).
130 (C) Crystal structure of the a/b-ligand with Bcl-XL (PDB: 4A1U). (D) Crystal structure of the aaab-ligand with Bcl-XL
(PDB: 4A1W).131 b-residue positions are highlighted with light-blue ribbon segments.
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20 and 21) caused more selective effects and led to discrimination between the two proteins, depending on the substitution
position.
p0380 To increase the cell penetration of the a/b-peptide, analogs were generated from a Bim BH3 domain-derived “stapled”
a-peptide. This contained a hydrocarbon cross-link and was able to enter certain cell types. The resulting foldamer effectively
mimicked the parent stapled peptide in its ability to enter cells and block apoptotic signaling. The results revealed that cyclization
of the staple was not necessary for cell entry and activity, but the combination of stapling and b-residue replacement can be
advantageous for the construction of active compounds with increased resistance to proteolysis.134
s0180 Helix mimicry with an oligoamide foldamer
p0385 Aromatic oligoamide foldamers are able to mimic the a-helix as concerns the side-chain functionalities and their geometric
presentation, without the need for the entire helical structure. A trispyridylamide scaffold was designed, which was stabilized by
a bifurcated hydrogen-bonding network withO-alkyl substituents as side chains. The functional epitopes are projected on the same
face of the molecule (Fig. 13A), mimicking i, i+4, i+7, and i+11 positions of the a-helix, which are often involved in target
recognition.12 Molecular mechanics calculations indicated that the backbone of the trispyridylamide scaffold with methoxy side
chains is quite planar, and the arrangement of the overlaid structure a-helix closely corresponded with the alanine side chains of the
helix. A number of designed trimeric sequences carrying isopropyloxy and benzyl side chains were bound to Bcl-xL with low
micromolar affinity (22–24; Fig. 13B) and inhibited the interaction with the BH3 peptide. Molecular modeling suggested that the
designed sequence is able to recognize the Bak recognition site of the BH3 domain.
s0185 Targeting the integrin aIIbb3 transmembrane (TM) domain
p0390 Targeting a TM region of a protein poses an additional barrier for the designed sequence, because insertion and orientation into the
TM region are prerequisites for the interaction with the protein domain. The a and b domains of integrin aIIbb3 associate in the
resting state, but the association is disrupted upon activation, with binding to the extracellular ligand fibrinogen.135 A ligand that
competes with this interaction should lead to fibrinogen activation. The successful design of a-peptide sequences with the help of a
computational method resulted in the CHAMP (computed helical antimembrane protein) peptides.136 The computational design
of CHAMP peptides begins with the selection of the backbone geometry for a specific peptide–target complex on the basis of known
membrane–protein structures and TM helix–helix pairs, and the optimum side chains are then selected.
p0395 This approach has been extended to the b-peptide 12- and 14-helical scaffolds, based on a previous CHAMP peptide that targets
the GXXXG motif on the aIIb sequence.
137 The initial design included an (hGly-X-X)3 motif with the hGly residues occupying one
face of the helix in the case of the 14-helical fold and a spiral around the 12-helix. The design included a number of apolar residues
in order to achieve a sufficiently long sequence capable of spanning through the membrane. Functionalization with tryptophan
and lysine side chains near the termini was carried out to govern the correct orientation of the helix in the lipid bilayer.
p0400 The CD spectrum of the b-CHAMP foldamer revealed a mixture of 14- and 12-helical conformations. Following the addition of
aIIb, the spectra suggested that b-CHAMP binds to the target in the 12-helix conformation. Analytic ultracentrifugation studies
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Fig. 13f0070 (A) Side-chain presentation of Bak BH3-derived peptide; epitope residues are highlighted in green. (B) Structures and Ki values of the designed
oligoamide foldamers.12
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revealed a 1:1 interaction between the b-CHAMP foldamer and the aIIb domain of the integrin. The designed b-CHAMP activated
aIIbb3 almost completely, and the opening of the complex was confirmed by TEM measurements.
s0190 b-Peptides against g-secretase
p0405 g-Secretase is an aspartyl protease that is located in the cell membrane and involved in the production of amyloid beta (Ab)
peptides by the proteolytic cleavage of APPs (amyloid precursor proteins).138 Inhibition of the activity of g-secretase could be
advantageous in the treatment of Alzheimer’s disease. It is suggested that, in its initial interactions with g-secretase, the TM domain
of APPs is helical, and it is assumed that small hydrophobic peptides can inhibit this interaction and the activity of the enzyme.
A number of peptides containing a-aminoisobutyric acid (Aib), a helix-inducing residue, have been found active in inhibiting the
production of Ab.139,140
p0410 The design of the b-peptide inhibitors started with the assumption that the enzyme cleaves highly hydrophobic, helical proteins.
trans-2-Aminocyclopentanecarboxylic acid (ACPC) was chosen to serve as building blocks for the synthesis of small helical
foldamers, since it is rather hydrophobic and ACPC oligomers exhibit a 12-helix structure, which is a close mimic of the a-helix.
The in vitro assay to quantify the Ab formed from recombinant substrates in the presence of an ACPC dodecamer yielded an
inhibitory potential of Ki¼5.2 nM.141 Structure–activity relationships with helicity-disrupted peptides revealed that the 12-helix
structure is crucial for the inhibitory effect, the length of the dodecamer is optimum, and the b-peptide directly targets the initial
substrate docking site of the enzyme. A number of analogs were constructed from this oligomer through substitution with
b3-amino acids.142 Further improvement was achieved by incorporating b3-hSer or b3-hAsn in position 3 of the parent peptide,
which was the only favorable substitution position. The incorporation of b3-hSer increased the inhibitory potential to
IC50¼0.4 nM.
s0195 HIV fusion protein inhibitors
p0415 The fusion mechanism of the HIV virus is governed by the rearrangement of the gp41 protein. The N-terminal trimeric fusion
segment is responsible for insertion into the host cell membrane, and structural rearrangement of the protein from a prehairpin
conformation results in the formation of a six-helix bundle that moves the viral and host membranes closer.143 Targeting this
conversion complex with individual helical structures originating from the gp41 N-terminal or C-terminal heptad repeat (NHR or
CHR) segments led to potent antifusion compounds.144,145 The surface pocket of the gp41 NHR timer is occupied by three a-helical
residues situated near the C-terminus of gp41. These residues are Trp628, Trp631, and Ile635, also known as the WWI Au8epitope.
s0200 Structure-based design of WWI epitope mimetics
p0420 The goal was to mimic the orientation and side-chain presentation of the WWI epitope by using b-peptide foldamers.146
A 14-helical salt-bridge and macrodipole-stabilized scaffold was used with appropriate side-chain presentation of the WWI epitope
(peptide 25; Fig. 14.), and lowmicromolar binding affinities were measured for a gp41model that displayed inhibitory activity in a
cell–cell fusion assay. The central side chain is thought to be crucial for the binding, and optimization was therefore carried out in
this position.147 A number of nonnatural side-chain modifications to halogen-substituted aromatic rings were carried out to probe
the steric and electronic effects. The affinity was improved following substitution with an m-trifluoromethylphenyl side chain
(compound 26), with a KD of 10.2 mM for a gp41 model system.
s0205 Sequence-based a/b-foldamers
p0425 A sequence-based approach was applied by using an inhibitor a-peptide (T-2635) derived from the CHR domain of gp41 (peptide
27; Fig. 15A) as starting point. a!b Substitutions carried out in an aabaaab pattern resulted in the positioning of b-residues distal
along the helix surface that interacts with the gp41 NHR domain trimer.149 The foldamers were tested against an engineered 5-helix
bundle protein gp41-5, which contains three NHR and two CHR segments. The designed a/b-foldamer displayed a more than
104-fold lower activity than that of the parent a-peptide. Application of a/b+a-chimera sequences revealed that the N-terminal
segment of the peptide is sensitive to modifications because several side chains play a crucial role in the recognition of the
NHR trimer.
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Fig. 14f0075 Sequences and affinities of the two designed foldamers against gp45. KD values were derived from direct fluorescent polarization assays of a
gp41 model and EC50 values from MTT assays reflecting 50% survival of the infected cells.
147
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p0430 It was concluded that the inserted b3-amino acids retained some residual flexibility, despite their helix-promoting effect, which
caused entropic loss upon binding, eventually leading to low activity. Substitution with the conformationally constrained amino
acids, ACPC and APC lowers the flexibility and enhances the helical folding propensity. Substitution with the rigidified cyclic
residues resulted in an 380-fold enhancement relative to the flexible a/b-peptide, with Ki of 9 nM (peptide 28).
p0435 The helix conformation was additionally stabilized by utilizing dense ionic side-chain pairing along one of the surfaces of the
helix.150 Stability against proteolysis and enhanced activity were achieved by the insertion of constrained residues into the already
stabilized helix (peptide 29; Ki<0.2 nM). In order to determine which residues are responsible for the relatively strong binding,
backward mutations and alanine scans were carried out. Together with the X-ray results (Fig. 15B), these findings revealed that a
broad range of interactions play basic roles in the binding, which explains the difficulty of finding a small-molecule inhibitor for
HIV fusion inhibitors.148
s0210 Interactions That Require a b-Sheet Fold
p0440 There are almost 15,000 high-affinity b-strand interacting pairs among protein–protein interactions, but these interfaces are less
frequently targeted.151 The reason for this lies in the challenges of the design of water-soluble b-sheet models that mimic structural
and functional features. Attempts to achieve sequence-guided a!b replacements of b-sheet models have been reported,25,152 but
the construction of sheets involving a/b-peptides is less straightforward than in the case of helices.
s0215 Mimics of an antiangiogenic b-sheet
p0445 Attempts to characterize the effects of b-amino acid substitutions in a complex b-sheet system have been made. A top-down
sequence-based approach was followed to test the suitability of a b-sheet for b3-amino acid substitutions in conjunction with an
investigation of biological activity.27 As amodel system, usewasmade of the three-stranded antiparallel b-sheet anginex (compound
30; Fig. 16), which has antiangiogenic and antitumor activities.153,154 The exact mechanism of action is not exactly understood, but
the prevailing conformation of anginex in the concentration range used in in vitro experiments is known to be random coil, and a
b-sheet folding propensity is required for its biological activity.155 Systematic b3-amino acid substitutions in the b-sheet region of the
peptide revealed that inducibility of the b-sheet fold can be maintained, and a number of analogs displayed biological activity close
Fig. 15f0080 (A) Sequences of the C-terminal heptad repeat (CHR) domain (27) and the designed a/b-foldamers (28, 29) with the corresponding affinities to
the gp41-5 protein and their stability against proteolytic degradation. (B) Crystal structure of a/b-foldamer 28 bound to gp41-5 (gray ribbon) (PDB:
3O43).148 b-Amino acid residues in the sequence and in the ribbon of the crystal structure are highlighted in light blue.
Fig. 16f0085 Sequence of the most potent anginex analogs, with IC50 values in mM derived from in vitro assay. The b-sheet-forming amino acids are situated
inside the square.
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to that of the parent peptide (compound 31; IC50¼27.9 mM). The reason behind the lack of activity of other analogs can be
explained by the torsion of the folded structure or the misalignment of key residues responsible for biological activity.
p0450 Further anginex analogs have been designed containing substitutions of conformationally constrained cyclic amino acids
(compound 32).156 These analogs exhibited diverse b-sheet contents, which could be further induced to different extents by
means of a membrane-mimicking environment. The inducibility, that is, the difference between the b-sheet content induced by
micelles and the noninduced conformation, correlated with the biological activity rather than the preexisting b-sheet content.
s0220 Complex or Structurally Undefined Interaction Interfaces
p0455 Protein–protein interfaces are often more complex and irregular than a single isolated secondary structure such as a helix, which
requires a topologically more complex interaction partner. Furthermore, targeting a protein with limited information relating to the
interaction surface excludes structure-based design approaches and requires high-throughput methods, such as library-based
approaches, to identify lead molecules.
s0225 Targeting amyloid beta
p0460 Soluble oligomers of Ab may contribute to learning and memory deficits in Alzheimer’s disease.157,158 The conformation of the
oligomers in vivo is unknown; various Ab interaction peptides159 and structural investigations160 have suggested the Ab(16–22)
segment (KLVFFAE) as a potential target on the surface of the oligomers. To target this surface, a fragment-based bottom-up design
was utilized with a small-membered library of different helical scaffolds,43 containing pure b-peptidic 14-, 12-, 10/12-, and
14/16-helices and one a/b 9/12-helix. The 14-helical structure with zwitterionic side chains was identified as the lead compound
via an NMR-based method and presented low micromolar affinity. The affinity was amplified by coupling the helices to a
G0-PAMAM dendrimer, which resulted in a tetravalent ligand (33; Fig. 17). The multivalency facilitated the recognition of the
repeating pattern of Ab and nanomolar affinity, and selectivity toward Ab oligomers was demonstrated.
p0465 Cyclic modular b-sheets created by combining peptides and a template that nucleates b-sheet folding could be an efficient tool
for the recognition of targets such as Ab that display repeating surface patterns.161 Macrocycles known as amyloid b-sheet mimics
(ABSMs) that tolerate a wide range of sequences from amyloid proteins have been designed. These ABSMs contain one recognition
edge, which presents the amyloidogenic sequence, and one blocking edge with the tripeptide Hao (comprising hydrazine, 5-amino-
2-methoxybenzoic acid, and oxalic acid groups), which promotes b-sheet formation by serving as a template for intramolecular
hydrogen bonds.162,163 The Hao unit is also responsible for the prevention of intermolecular aggregation by minimizing the
hydrogen-bonding functionality at the edge. Without ABSMs, unstructured Abmonomers form a b-sheet-structured nucleus, which
assembles to oligomers and fibrils. An ABSM binds b-structured oligomers, thereby creating a new aggregation pathway, and the
Hao molecules prevent further aggregation and block the process in a low-molecular-weight oligomer state. The ABSM containing
the KLVFFAE sequence from Ab displayed effective inhibition of Ab1–42 aggregation with a 350% delay at 0.2 equiv. and a 600%
delay at 0.5 equiv. of ABSM.
s0230 Targeting the vascular endothelial growth factor (VEGF) receptor recognition surface
p0470 VEGF interacts with cell surface VEGF receptors 1 and 2, which participate in angiogenesis,164 and inhibition of these interactions
may therefore be effective in cancer treatment.165 This system is a good model with which to study diverse protein–protein
interfaces, because the interaction interface involves segments without a regular secondary structure. By phage display, a 19-mer
peptide v114 was optimized (34; Fig. 18), which binds to the receptor recognition patch on the VEGF.167 This was utilized as
starting point for a sequence-based design of a/b-foldameric analogs. A systematic alanine and b3 scan revealed that point
mutations to b3-amino acids were better tolerated than alanine substitutions.166 Replacement with cyclic b-amino acids had little
effect on the affinity. The regular b-amino acid substitution patterns for a-helix mimicry are not suitable in this particular case, and
multiple substitutions were therefore carried out in positions where a!b replacements were tolerated. Such multiple substitutions
led to lower activity, depending on the substitution positions, but were accompanied by increased proteolytic stability (35 and 36).
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Fig. 17f0090 Structure of the foldamer–dendrimer conjugate and its binding affinity to Ab oligomers measured using ITC.43 TMP, tetra-maleimidopropionyl-
G0-PAMAM.
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s0235 Targeting diverse protein surfaces with foldameric analogs of the Z-domain scaffold
p0475 Another approach to construct a/b-peptides that bind to VEGF is to utilize the Z-domain scaffold. The Z domain or “affibody”168 is
a 3-helix bundle domain engineered from domain B of staphylococcal protein A.169 It is a 58-residue analog of domain B, which
retains affinity for the Fc portion IgG (Z-IgG). The surfaces of helices 1 and 2 (>600 A˚2) are responsible for interaction with Fc,
while the third helix stabilizes the folding. The solvent-exposed surface of the Z domain tolerates substitution carried out to create
binding patches to diverse protein partners,170 which resulted in optimized Z-domain derivatives that bind, for example, to VEGF
(Z-VEGF) 171 or tumor necrosis factor-a (Z-TNFa).172
p0480 The Z-VEGF was used to perform a!b replacements with the hypothesis that substitutions distinct from the recognition sites
would maintain affinity with improved proteolytic stability.173 The design involved a truncation of the 3-helix bundle to a 2-helix
analog by removal of the third helix and stabilization by a disulfide bridge (37; Fig. 19). This led to binding to the VEGF165 dimer
with Ki¼0.4 mM. Substitutions were carried out with constrained residues, which were capable of increasing the activity, most
probably because of the enhanced folding propensity. Several tolerated substitution positions were found, which resulted in an
analog containing a number of substitutions in the N-terminal segment and both helices in the peptide, with a Ki of 0.11 mM (38).
These are the first examples of a potent a/b-peptide that is shorter than the parent peptide. Proteolytic stability measurements
revealed increased stability against proteinase K: The half-life of the Z-VEGF is 1.6 min, whereas that of the a/b-peptide is 59 min;
additional introduction of Aib residues increased the half-life to 670 min (39). The crystal structure of the complex with the
VEGF8–109 homodimer revealed that the foldamer binds to the equivalent receptor site of Z-VEGF.
p0485 The design approach was extended to two Z-domain scaffolds that bind to IgG (Z-IgG) and TNFa (Z-TNFa). The designed
a/b-analogs exhibited similar affinity to those of the original peptide, and the selectivity for target proteins was also retained. This
approach appears to be general for Z domain-derived a/b-peptide design.
s0240 Foldamers Mimicking G Protein-Coupled Receptor (GPCR) Ligands
p0490 Achievement of the molecular recognition mechanism for receptor activation can be a challenging task, because of the strict
binding requirements of the receptor. The discovery of b- and a/b-peptides that can serve as receptor-binding foldamers is based
exclusively on a sequence-based design approach targeting GPCRs. GPCRs are responsible for a variety of signal transductions from
the extracellular stimuli experienced by the cell. Small molecules, peptides, and small proteins are found among GPCR ligands,174
and this facilitates the design of analogous foldamers. Among the earliest examples were the designed cyclic b-tetrapeptide analogs
of octreotide, which bound to the somatostatin receptor.175
p0495 A few examples are presented in the succeeding text to illustrate designed GPCR foldamer ligands involving multiple
substitutions with nonnatural amino acids or b-peptide structures. For a detailed review of GPCR-targeting peptide analogs
containing b-amino acid substitutions, see Ref. 176.
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Fig. 18f0095 The sequence of the most potent VEGF-binding foldamers. Ki values are derived from competitive FP assays, and measured half-lives are based
on proteinase K assays.166 All peptides contain an intramolecular disulfide bond between the Cys residues (underlined).
Fig. 19f0100 (A) Sequence and (B) crystal structure of the most potent a/b-Z-VEGF foldamer bound to the VEGF (PDB: 4WPB).173 Nonnatural residues
are highlighted in light blue in the sequence and the ribbon of the crystal structure. All peptides contain an intramolecular disulfide bond between the Cys
residues (underlined).
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s0245 Parathyroid hormone (PTH) analogs
p0500 PTH regulates the blood calcium levels through GPCRs. The N-terminus of PTH1–34, a peptide used in the clinical treatment of
osteoporosis, interacts with the TM domain of the GPCR and is responsible for signaling. Residues 15–34 fold into an a-helix with
high affinity for the GPCR extracellular domain.177 Sequence-based design with b3-residue replacements in an aaab pattern has
been utilized to generate a PTH1–34 analog with comparable receptor-binding affinity.
178 In vivo effectiveness was also proved:
a/b-PTH1–34 caused identical spikes in the blood calcium levels, and the foldamer was capable of sustaining the calcium levels for
several hours after administration, while treatment with the a-peptide resulted in a faster return of the calcium level to the baseline.
The serum levels of the peptide hormones suggested that the higher proteolytic stability of the a/b analogs was responsible for this
effect.
s0250 Glucagon-like peptide-1 (GLP-1) analogs
p0505 The receptor is activated by the 30-mer peptide hormone GLP-1 or the analog peptide exendin-4, which is responsible for glucose-
dependent insulin release. The well-defined C-terminal helix of GLP-1 or exendin-4 probably participates in receptor binding.
A hybrid foldamer was designed in which the receptor-activating residues were intact and connected via a PEG Au9linker to a b-peptide
14-helix and proved to have 106-fold lower activity than that of the endogenous ligand.179
p0510 a!b3 substitutions were not tolerated; the replacement of three residues resulted in the loss of activity. Cyclic b-amino acid
substitutions were better tolerated in an aaab pattern.180 The N-terminal segment was sensitive to backbone alterations; known
proteolytic cleavage sites were blocked through the use of Aib. The a/b-analog demonstrated in vitro and in vivo activity, with a
more sustained effect of glucose tolerance, as a result of the higher proteolytic stability.
s0255 Recognition Interfaces Involving Saccharide Moieties
s0260 Heparin Inhibitor Foldamers
p0515 Heparin or unfractionated heparin (UFH) is a sulfated glycosaminoglycan used clinically for the prevention of blood clots. The
only agent that reverses its activity is protamine, an arginine-rich peptide that binds to UFH.181 There are no agents that reverse the
activity of low-molecular-weight heparins (LMWHs).
p0520 The design of self-associating foldamers targeting heparin was based on electrostatic interactions.182 The first scaffold was a
1,3-substituted arylamide oligomeric backbone, which was functionalized to provide cationic side chains. The most potent
structures had IC50 values of 22.5 mM for inhibition of the LMWH–antithrombin interaction.
p0525 A foldameric scaffold consisting of a-amino acids and salicylamide (Sal) in an alternating manner has also been utilized against
heparin; this self-associates into a two-stranded antiparallel sheet structure.183 In the absence of the pentasaccharide analog of
heparin, fondaparinux, the foldamer favored the monomer state, and the active, associated form was obtained in the presence of
fondaparinux. A highly potent foldamer, H2N-(Lys-Sal)4-CONH2, exhibited activity in a standard activated partial thromboplastin
time assay (IC50¼1.1 mM). Foldamers without the ability to undergo self-association did not display activity. The replacement of
lysine by the neutral citrulline resulted in a self-associating foldamer, but loss of the cationic side chains led to lower activity.
s0265 Glycopeptide Mimics
p0530 The glycosylation of proteins is a common posttranslational modification and plays an important role in recognition processes.
N-Acetylgalactosamine side chains were introduced into b-peptides through O-glycosyl modification of the b3-amino acid mono-
mers, yielding glycopeptide mimetic structures, which were tested against various sugar-binding proteins, lectins.184 Improvement
of the affinity and selectivity toward different lectins was not achieved via utilization of the 14-helical foldamers containing the
glycosyl moiety; however, NMR measurements indicated the direct contact of the b-peptide helix and the protein.185
p0535 Structure–affinity investigations were carried out on d-sugar amino acid foldamers to investigate the influence of the appended
sugars on the secondary structure and the lectin-binding affinity.186 The appended mannosyl units caused a conformational shift
from a 10-membered H-bonded structure to a 16-membered structure in water, which depended on the configuration of the
monomeric units (compounds 40–43; Fig. 20A). A conformational switch was observed only for the cis-monomer backbone.
p0540 Tests of two helices on the lectins concanavalin A and FimH from E. coli, which are known to bind mannopyranosyl and
terminal a-d-mannosyl units, respectively, revealed that the 16-membered turn secondary structure was more potent in lectin
binding (Fig. 18B).
s0270 Conclusions and Outlook
p0545 Molecular recognition requires a complementary contact surface between the interaction partners that is large enough to shield the
interface from the solvent and to accommodate a number of functional groups stabilizing the complex. Foldamers have program-
mable shapes andmostly independently adjustable anchor points over their surface. These features are accompanied by a moderate
size, which is large enough to exclude solvent from the contact surface, but considerably smaller than that of proteins.
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This combination of the structural features facilitates the synthesis of oligomeric molecules able to bind chemically diverse and
biologically relevant interaction partners ranging from small molecules to macromolecules. The results presented here demonstrate
the geometric versatility of foldamers. It is possible to wrap the artificial chains around a small molecule, thereby forming a stable
host–guest complex. On the other hand, the tailor-made outer surfaces of these intriguing sequences can be utilized for recognition
of the solvent-exposed surface patches of proteins and DNA. Moreover, the tunable structures facilitate interactions of a dynamic
nature, such as membrane recognition and penetration.
p0550 Unlike natural peptides/proteins, these sequences cannot be optimized by using evolutionary methods; however, their limited
size affords chemical space-searching methods, which place new chemical entities within reach if the structure of the target or the
specific protein–protein interface is known at reasonably high resolution. There have been a number of examples of structure-,
sequence-, and fragment-based designs, though it must be emphasized that the efficiency of these theoretically separate approaches
is currently limited. Although rules have been observed for the structural and biological effects of the unnatural building block
replacements in natural sequences, an improved understanding is needed, especially for the novel building blocks and for
structures with complexity beyond that of a stand-alone helix. The de novo design approaches are promising; decoupling the
effects of the scaffold from those of the interacting side chains appears to be a powerful method, and the structure- and fragment-
based methods deserve further attention. Their combination with the principles of dynamic covalent chemistry may prove efficient
in the future for the targeting of proteins without well-defined hot spots over their surface.
p0555 The findings presented in this article clearly indicate that foldamers can act as protein mimetics in terms of molecular
recognition. From the aspect of biomedical applications, foldamers have advantages over biopharmaceuticals. Their synthesis
results in compounds with well-defined chemical structures, which is preferred to the less well-defined mixture nature of antibody
therapeutics. Moreover, foldamers are not substrates for proteinases, and their size is tunable without loss of structure. These factors
offer the possibility of advantageous in vivo pharmacokinetics, which is a prerequisite of biomedical applications. We close this
article with the hope that foldamers will not only demonstrate their utility as a molecular recognition toolbox but also prove
helpful to patients with currently incurable diseases.
References
1. Goodman, C. M.; Choi, S.; Shandler, S.; Degrado, W. F. Foldamers as Versatile Frameworks for the Design and Evolution of Function. Nat. Chem. Biol. 2007, 3(5), 252–262.
2. Zhang, D.-W.; Zhao, X.; Li, Z.-T. Aromatic Amide and Hydrazide Foldamer-Based Responsive Host–Guest Systems. Acc. Chem. Res. 2014, 47(7), 1961–1970.
3. Zhang, D.-W.; Zhao, X.; Hou, J.-L.; Li, Z.-T. Aromatic Amide Foldamers: Structures, Properties, and Functions. Chem. Rev. 2012, 112(10), 5271–5316.
4. Huc, I. Aromatic Oligoamide Foldamers. Eur. J. Org. Chem. 2004, 2004(1), 17–29.
5. Li, Z. T.; Hou, J. L.; Li, C.; Yi, H. P. Shape-Persistent Aromatic Amide Oligomers: New Tools for Supramolecular Chemistry. Chem. Asian J. 2006, 1(6), 766–778.
6. Fulop, F.; Martinek, T. A.; Toth, G. K. Application of Alicyclic Beta-Amino Acids in Peptide Chemistry. Chem. Soc. Rev. 2006, 35(4), 323–334.
7. Martinek, T. A.; Fu¨lo¨p, F. Peptidic Foldamers: Ramping Up Diversity. Chem. Soc. Rev. 2012, 41(2), 687–702.
8. Pilsl, L. K.; Reiser, O. a/b-Peptide Foldamers: State of the Art. Amino Acids 2011, 41(3), 709–718.
9. Horne, W. S.; Gellman, S. H. Foldamers With Heterogeneous Backbones. Acc. Chem. Res. 2008, 41(10), 1399–1408.
10. Jiang, H.; Le´ger, J.-M.; Dolain, C.; Guionneau, P.; Huc, I. Aromatic d-Peptides: Design, Synthesis and Structural Studies of Helical, Quinoline-Derived Oligoamide Foldamers.
Tetrahedron 2003, 59(42), 8365–8374.
11. Yi, H.-P.; Shao, X.-B.; Hou, J.-L.; Li, C.; Jiang, X.-K.; Li, Z.-T. Hydrogen Bonding-Mediated Oligobenzamide Foldamer Receptors That Efficiently Bind a Triol and Saccharides in
Chloroform. New J. Chem. 2005, 29(9), 1213–1218.
Comp. by: MSanthiya Stage: Proof Chapter No.: 12547 Title Name: SMC2
Date:25/6/16 Time:06:54:34 Page Number: 22
Fig. 20f0105 (A) Sequence and structures of the d-sugar amino acid foldamers in methanol (40 and 42) and in water (41 and 43). (B) Lectin-binding
activity Au1in different assays: concanavalin A (ConA) binding assessed by enzyme-linked lectin assay; E. coli cell adhesion inhibitory titers and competitive
binding to T24 bladder cells.
22 Molecular Recognition Using Foldamers
SMC2: 12547
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only by the author(s), editor(s), reviewer(s), Elsevier and
typesetter SPi. It is not allowed to publish this proof online or in print. This proof copy is the copyright property of the publisher and is confidential until formal publication.
These proofs may contain colour figures. Those figures may print black and white in the final printed book if a colour print product has not been planned. The colour figures will appear in
colour in all electronic versions of this book.
12. Ernst, J. T.; Becerril, J.; Park, H. S.; Yin, H.; Hamilton, A. D. Design and Application of an a-Helix-Mimetic Scaffold Based on an Oligoamide-Foldamer Strategy: Antagonism of the
Bak BH3/Bcl-xL Complex. Angew. Chem. 2003, 115(5), 553–557.
13. Gong, B.; Zeng, H.; Zhu, J.; Yua, L.; Han, Y.; Cheng, S.; Furukawa, M.; Parra, R. D.; Kovalevsky, A. Y.; Mills, J. L. Creating Nanocavities of Tunable Sizes: Hollow Helices. Proc.
Natl. Acad. Sci. 2002, 99(18), 11583–11588.
14. Dolain, C.; Jiang, H.; Le´ger, J.-M.; Guionneau, P.; Huc, I. Chiral Induction in Quinoline-Derived Oligoamide Foldamers: Assignment of Helical Handedness and Role of Steric
Effects. J. Am. Chem. Soc. 2005, 127(37), 12943–12951.
15. Seebach, D.; Beck, A. K.; Bierbaum, D. J. The World of b- and G-Peptides Comprised of Homologated Proteinogenic Amino Acids and Other Components. Chem. Biodivers.
2004, 1(8), 1111–1239.
16. Fu¨lo¨p, F.; Martinek, T. A.; To´th, G. K. Application of Alicyclic b-Amino Acids in Peptide Chemistry. Chem. Soc. Rev. 2006, 35(4), 323–334.
17. Werner, H. M.; Horne, W. S. Folding and Function in a/b-Peptides: Targets and Therapeutic Applications. Curr. Opin. Chem. Biol. 2015, 28, 75–82.
18. Au10Seebach, D.; Matthews, J. L. b-Peptides: A Surprise at Every Turn. Chem. Commun. 1997, 21(21), 2015–2022.
19. Szolnoki, E´.; Hete´nyi, A.; Ma´ndity, I. M.; Fu¨lo¨p, F.; Martinek, T. A. Foldameric b-H18/20P Mixed Helix Stabilized by Head-to-Tail Contacts: A Way to Higher-Order Structures. Eur.
J. Org. Chem. 2013, 2013(17), 3555–3559.
20. Szolnoki, E´.; Hete´nyi, A.; Martinek, T. A.; Szakonyi, Z.; Fu¨lo¨p, F. Self-Association-Driven Transition of the b-Peptidic H12 Helix to the H18 Helix. Org. Biomol. Chem. 2012, 10(2),
255–259.
21. Berlicki, Ł.; Pilsl, L.; We´ber, E.; Ma´ndity, I. M.; Cabrele, C.; Martinek, T. A.; Fu¨lo¨p, F.; Reiser, O. Unique a,b- and a,a,b,b-Peptide Foldamers Based on cis-b-
Aminocyclopentanecarboxylic Acid. Angew. Chem. Int. Ed. 2012, 51(9), 2208–2212.
22. Ma´ndity, I. M.; We´ber, E.; Martinek, T. A.; Olajos, G.; To´th, G. K.; Vass, E.; Fu¨lo¨p, F. Design of Peptidic Foldamer Helices: A Stereochemical Patterning Approach. Angew. Chem.
2009, 121(12), 2205–2209.
23. Au11Fisher, B. F.; Guo, L.; Dolinar, B. S.; Guzei, I. A.; Gellman, S. H. Heterogeneous H-Bonding in a Foldamer Helix. J. Am. Chem. Soc. 2015, 137, 6484–6487.
24. Giuliano, M. W.; Maynard, S. J.; Almeida, A. M.; Guo, L.; Guzei, I. A.; Spencer, L. C.; Gellman, S. H. A g-Amino Acid That Favors 12/10-Helical Secondary Structure in
a/g-Peptides. J. Am. Chem. Soc. 2014, 136(42), 15046–15053.
25. Lengyel, G. A.; Horne, W. S. Design Strategies for the Sequence-Based Mimicry of Side-Chain Display in Protein Beta-Sheets by Alpha/Beta-Peptides. J. Am. Chem. Soc. 2012,
134(38), 15906–15913.
26. Reinert, Z. E.; Lengyel, G. A.; Horne, W. S. Protein-Like Tertiary Folding Behavior From Heterogeneous Backbones. J. Am. Chem. Soc. 2013, 135(34), 12528–12531.
27. Hegedu¨s, Z.; We´ber, E.; Kriston-Pa´l, E.; Makra, I.; Czibula, A.; Monostori, E.; Martinek, T. A. Foldameric a/b-Peptide Analogs of the b-Sheet-Forming Antiangiogenic Anginex:
Structure and Bioactivity. J. Am. Chem. Soc. 2013, 135(44), 16578–16584.
28. Olajos, G.; Hete´nyi, A.; We´ber, E.; Ne´meth, L. J.; Szakonyi, Z.; Fu¨lo¨p, F.; Martinek, T. A. Induced Folding of Protein-Sized Foldameric b-Sandwich Models With Core b-Amino
Acid Residues. Chemistry 2015, 21(16), 6173–6180.
29. Spencer, R.; Chen, K. H.; Manuel, G.; Nowick, J. S. Recipe for b-Sheets: Foldamers Containing Amyloidogenic Peptide Sequences. Eur. J. Org. Chem. 2013, 2013(17),
3523–3528.
30. Ma´ndity, I. M.; Olasz, B.; O¨tvo¨s, S. B.; Fu¨lo¨p, F. Continuous-Flow Solid-Phase Peptide Synthesis: A Revolutionary Reduction of the Amino Acid Excess. ChemSusChem 2014,
7(11), 3172–3176.
31. Fowler, S. A.; Blackwell, H. E. Structure-Function Relationships in Peptoids: Recent Advances Toward Deciphering the Structural Requirements for Biological Function. Org.
Biomol. Chem. 2009, 7(8), 1508–1524.
32. Sun, J.; Zuckermann, R. N. Peptoid Polymers: A Highly Designable Bioinspired Material. ACS Nano 2013, 7(6), 4715–4732.
33. Juwarker, H.; Suk, J.-M.; Jeong, K.-S. Foldamers With Helical Cavities for Binding Complementary Guests. Chem. Soc. Rev. 2009, 38(12), 3316–3325.
34. Garric, J.; Le´ger, J.-M.; Huc, I. Molecular Apple Peels. Angew. Chem. Int. Ed. 2005, 44(13), 1954–1958.
35. Chandramouli, N.; Ferrand, Y.; Lautrette, G.; Kauffmann, B.; Mackereth, C. D.; Laguerre, M.; Dubreuil, D.; Huc, I. Iterative Design of a Helically Folded Aromatic Oligoamide
Sequence for the Selective Encapsulation of Fructose. Nat. Chem. 2015, 7(4), 334–341.
36. Hart, S. A.; Bahadoor, A. B. F.; Matthews, E. E.; Qiu, X. J.; Schepartz, A. Helix Macrodipole Control of b3-Peptide 14-Helix Stability in Water. J. Am. Chem. Soc. 2003, 125(14),
4022–4023.
37. Azzarito, V.; Miles, J. A.; Fisher, J.; Edwards, T. A.; Warriner, S. L.; Wilson, A. J. Stereocontrolled Protein Surface Recognition Using Chiral Oligoamide Proteomimetic Foldamers.
Chem. Sci. 2015, 6(4), 2434–2443.
38. Azzarito, V.; Long, K.; Murphy, N. S.; Wilson, A. J. Inhibition of Alpha-Helix-Mediated Protein–Protein Interactions Using Designed Molecules. Nat. Chem. 2013, 5(3), 161–173.
39. Horne, W. S.; Price, J. L.; Gellman, S. H. Interplay Among Side Chain Sequence, Backbone Composition, and Residue Rigidification in Polypeptide Folding and Assembly. Proc.
Natl. Acad. Sci. 2008, 105(27), 9151–9156.
40. Cheloha, R. W.; Sullivan, J. A.; Wang, T.; Sand, J. M.; Sidney, J.; Sette, A.; Cook, M. E.; Suresh, M.; Gellman, S. H. Consequences of Periodic a-to-b3 Residue Replacement for
Immunological Recognition of Peptide Epitopes. ACS Chem. Biol. 2015, 10(3), 844–854.
41. Peterson-Kaufman, K. J.; Haase, H. S.; Boersma, M. D.; Lee, E. F.; Fairlie, W. D.; Gellman, S. H. Residue-Based Preorganization of BH3-Derived a/b-Peptides: Modulating
Affinity, Selectivity and Proteolytic Susceptibility in a-Helix Mimics. ACS Chem. Biol. 2015, 10(7), 1667–1675.
42. Scott, D. E.; Coyne, A. G.; Hudson, S. A.; Abell, C. Fragment-Based Approaches in Drug Discovery and Chemical Biology. Biochemistry 2012, 51(25), 4990–5003.
43. Fulop, L.; Mandity, I. M.; Juhasz, G.; Szegedi, V.; Hetenyi, A.; Weber, E.; Bozso, Z.; Simon, D.; Benko, M.; Kiraly, Z.; Martinek, T. A. A Foldamer-Dendrimer Conjugate Neutralizes
Synaptotoxic Beta-Amyloid Oligomers. PLoS One 2012, 7(7), e39485.
44. Guarise, C.; Shinde, S.; Kibler, K.; Ghirlanda, G.; Prins, L. J.; Scrimin, P. A Multivalent HIV-1 Fusion Inhibitor Based on Small Helical Foldamers. Tetrahedron 2012, 68(23),
4346–4352.
45. Au12Knight, A. S.; Zhou, E. Y.; Francis, M. B.; Zuckermann, R. N. Sequence Programmable Peptoid Polymers for Diverse Materials Applications. Adv. Mater. 2015, 27, 5665–5691.
46. Kritzer, J. A.; Luedtke, N. W.; Harker, E. A.; Schepartz, A. A Rapid Library Screen for Tailoring b-Peptide Structure and Function. J. Am. Chem. Soc. 2005, 127(42),
14584–14585.
47. Sadowsky, J. D.; Murray, J. K.; Tomita, Y.; Gellman, S. H. Exploration of Backbone Space in Foldamers Containing a- and b-Amino Acid Residues: Developing Protease-Resistant
Oligomers That Bind Tightly to the BH3-Recognition Cleft of Bcl-xL. ChemBioChem 2007, 8(8), 903–916.
48. Berl, V.; Krische, M. J.; Huc, I.; Lehn, J.-M.; Schmutz, M. Template-Induced and Molecular Recognition Directed Hierarchical Generation of Supramolecular Assemblies From
Molecular Strands. Chemistry 2000, 6(11), 1938–1946.
49. Chenga´zeng, X. Crescent Oligoamides as Hosts: Conformation-Dependent Binding Specificity. Org. Biomol. Chem. 2009, 7(18), 3643–3647.
50. Ong, W. Q.; Zhao, H.; Fang, X.; Woen, S.; Zhou, F.; Yap, W.; Su, H.; Li, S. F.Y; Zeng, H. Encapsulation of Conventional and Unconventional Water Dimers by Water-Binding
Foldamers. Org. Lett. 2011, 13(12), 3194–3197.
51. Zhao, H.; Ong, W. Q.; Fang, X.; Zhou, F.; Hii, M. N.; Li, S. F.Y; Su, H.; Zeng, H. Synthesis, Structural Investigation and Computational Modelling of Water-Binding Aquafoldamers.
Org. Biomol. Chem. 2012, 10(6), 1172–1180.
52. Garric, J.; Le´ger, J.-M.; Huc, I. Encapsulation of Small Polar Guests in Molecular Apple Peels. Chem. Eur. J. 2007, 13(30), 8454–8462.
53. Bao, C.; Kauffmann, B.; Gan, Q.; Srinivas, K.; Jiang, H.; Huc, I. Converting Sequences of Aromatic Amino Acid Monomers Into Functional Three-Dimensional Structures: Second-
Generation Helical Capsules. Angew. Chem. Int. Ed. 2008, 47(22), 4153–4156.
54. Ferrand, Y.; Kendhale, A. M.; Kauffmann, B.; Gre´lard, A.; Marie, C.; Blot, V.; Pipelier, M.; Dubreuil, D.; Huc, I. Diastereoselective Encapsulation of Tartaric Acid by a Helical
Aromatic Oligoamide. J. Am. Chem. Soc. 2010, 132(23), 7858–7859.
Comp. by: MSanthiya Stage: Proof Chapter No.: 12547 Title Name: SMC2
Date:25/6/16 Time:06:54:37 Page Number: 23
Molecular Recognition Using Foldamers 23
SMC2: 12547
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only by the author(s), editor(s), reviewer(s), Elsevier and
typesetter SPi. It is not allowed to publish this proof online or in print. This proof copy is the copyright property of the publisher and is confidential until formal publication.
These proofs may contain colour figures. Those figures may print black and white in the final printed book if a colour print product has not been planned. The colour figures will appear in
colour in all electronic versions of this book.
55. Abramyan, A. M.; Liu, Z.; Pophristic, V. Mechanistic and Dynamic Insights Into Ligand Encapsulation by Helical Arylamide Foldamers. Phys. Chem. Chem. Phys. 2014, 16(38),
20406–20410.
56. Kendhale, A. M.; Poniman, L.; Dong, Z.; Laxmi-Reddy, K.; Kauffmann, B.; Ferrand, Y.; Huc, I. Absolute Control of Helical Handedness in Quinoline Oligoamides. J. Org. Chem.
2010, 76(1), 195–200.
57. Ferrand, Y.; Chandramouli, N.; Kendhale, A. M.; Aube, C.; Kauffmann, B.; Gre´lard, A.; Laguerre, M.; Dubreuil, D.; Huc, I. Long-Range Effects on the Capture and Release of a
Chiral Guest by a Helical Molecular Capsule. J. Am. Chem. Soc. 2012, 134(27), 11282–11288.
58. Lautrette, G.; Kauffmann, B.; Ferrand, Y.; Aube, C.; Chandramouli, N.; Dubreuil, D.; Huc, I. Structure Elucidation of Host–Guest Complexes of Tartaric and Malic Acids by Quasi-
Racemic Crystallography. Angew. Chem. Int. Ed. 2013, 52(44), 11517–11520.
59. Lautrette, G.; Aube, C.; Ferrand, Y.; Pipelier, M.; Blot, V.; Thobie, C.; Kauffmann, B.; Dubreuil, D.; Huc, I. Tuning the Guest-Binding Ability of a Helically Folded Capsule by In Situ
Modification of the Aromatic Oligoamide Backbone. Chem. Eur. J. 2014, 20(6), 1547–1553.
60. Hou, J.-L.; Shao, X.-B.; Chen, G.-J.; Zhou, Y.-X.; Jiang, X.-K.; Li, Z.-T. Hydrogen Bonded Oligohydrazide Foldamers and Their Recognition for Saccharides. J. Am. Chem. Soc.
2004, 126(39), 12386–12394.
61. Li, C.; Wang, G.-T.; Yi, H.-P.; Jiang, X.-K.; Li, Z.-T.; Wang, R.-X. Diastereomeric Recognition of Chiral Foldamer Receptors for Chiral Glucoses. Org. Lett. 2007, 9(9), 1797–1800.
62. Inouye, M.; Waki, M.; Abe, H. Saccharide-Dependent Induction of Chiral Helicity in Achiral Synthetic Hydrogen-Bonding Oligomers. J. Am. Chem. Soc. 2004, 126(7),
2022–2027.
63. Abe, H.; Masuda, N.; Waki, M.; Inouye, M. Regulation of Saccharide Binding With Basic Poly(ethynylpyridine)s by H+-Induced Helix Formation. J. Am. Chem. Soc. 2005,
127(46), 16189–16196.
64. Abe, H.; Machiguchi, H.; Matsumoto, S.; Inouye, M. Saccharide Recognition-Induced Transformation of PyridinePyridone Alternate Oligomers From Self-Dimer to Helical
Complex. J. Org. Chem. 2008, 73(12), 4650–4661.
65. Prince, R. B.; Barnes, S. A.; Moore, J. S. Foldamer-Based Molecular Recognition. J. Am. Chem. Soc. 2000, 122(12), 2758–2762.
66. Stone, M. T.; Moore, J. S. A Water-Soluble m-Phenylene Ethynylene Foldamer. Org. Lett. 2004, 6(4), 469–472.
67. Tanatani, A.; Mio, M. J.; Moore, J. S. Chain Length-Dependent Affinity of Helical Foldamers for a Rodlike Guest. J. Am. Chem. Soc. 2001, 123(8), 1792–1793.
68. Tanatani, A.; Hughes, T. S.; Moore, J. S. Foldamers as Dynamic Receptors: Probing the Mechanism of Molecular Association Between Helical Oligomers and Rodlike Ligands.
Angew. Chem. 2002, 114(2), 335–338.
69. Goto, K.; Moore, J. S. Sequence-Specific Binding of m-Phenylene Ethynylene Foldamers to a Piperazinium Dihydrochloride Salt. Org. Lett. 2005, 7(9), 1683–1686.
70. Xiao, Z.-Y.; Hou, J.-L.; Jiang, X.-K.; Li, Z.-T.; Ma, Z. Complexes Between Hydrogen Bonded Bisporphyrin Tweezers and Cholesterol-Appended Fullerenes As Organogelators and
Liquid Crystals. Tetrahedron 2009, 65(49), 10182–10191.
71. Feng, D.-J.; Wang, G.-T.; Wu, J.; Wang, R.-X.; Li, Z.-T. Hydrogen Bonding-Driven Elastic Bis (Zinc) Porphyrin Receptors for Neutral and Cationic Electron-Deficient Guests With a
Sandwich-Styled Complexing Pattern. Tetrahedron Lett. 2007, 48(35), 6181–6185.
72. Hou, J. L.; Yi, H. P.; Shao, X. B.; Li, C.; Wu, Z. Q.; Jiang, X. K.; Wu, L. Z.; Tung, C. H.; Li, Z. T. Helicity Induction in Hydrogen-Bonding-Driven Zinc Porphyrin Foldamers by Chiral
C60-Incorporating Histidines. Angew. Chem. 2006, 118(5), 810–814.
73. Juwarker, H.; Jeong, K.-S. Anion-Controlled Foldamers. Chem. Soc. Rev. 2010, 39(10), 3664–3674.
74. Miller, J. P.; Melicher, M. S.; Schepartz, A. Positive Allostery in Metal Ion Binding by a Cooperatively Folded b-Peptide Bundle. J. Am. Chem. Soc. 2014, 136(42),
14726–14729.
75. Zasloff, M. Antimicrobial Peptides of Multicellular Organisms. Nature 2002, 415(6870), 389–395.
76. Hamuro, Y.; Schneider, J. P.; Degrado, W. F. De Novo Design of Antibacterial b-Peptides. J. Am. Chem. Soc. 1999, 121(51), 12200–12201.
77. Liu, D.; Degrado, W. F. De Novo Design, Synthesis, and Characterization of Antimicrobial b-Peptides. J. Am. Chem. Soc. 2001, 123(31), 7553–7559.
78. Porter, E. A.; Wang, X.; Lee, H.-S.; Weisblum, B.; Gellman, S. H. Antibiotics: Non-Haemolytic b-Amino-Acid Oligomers. Nature 2000, 404(6778), 565.
79. Raguse, T. L.; Porter, E. A.; Weisblum, B.; Gellman, S. H. Structure-Activity Studies of 14-Helical Antimicrobial b-Peptides: Probing the Relationship Between Conformational
Stability and Antimicrobial Potency. J. Am. Chem. Soc. 2002, 124(43), 12774–12785.
80. Porter, E. A.; Weisblum, B.; Gellman, S. H. Use of Parallel Synthesis to Probe Structure-Activity Relationships Among 12-Helical b-Peptides: Evidence of a Limit on Antimicrobial
Activity. J. Am. Chem. Soc. 2005, 127(32), 11516–11529.
81. Schmitt, M. A.; Weisblum, B.; Gellman, S. H. Interplay Among Folding, Sequence, and Lipophilicity in the Antibacterial and Hemolytic Activities of a/b-Peptides. J. Am. Chem.
Soc. 2007, 129(2), 417–428.
82. Epand, R. F.; Schmitt, M. A.; Gellman, S. H.; Sen, A.; Auger, M.; Hughes, D. W.; Epand, R. M. Bacterial Species Selective Toxicity of Two Isomeric a/b-Peptides: Role of
Membrane Lipids. Mol. Membr. Biol. 2005, 22(6), 457–469.
83. Epand, R. F.; Schmitt, M. A.; Gellman, S. H.; Epand, R. M. Role of Membrane Lipids in the Mechanism of Bacterial Species Selective Toxicity by Two a/b-Antimicrobial Peptides.
Biochim. Biophys. Acta 2006, 1758(9), 1343–1350.
84. Karlsson, A. J.; Pomerantz, W. C.; Weisblum, B.; Gellman, S. H.; Palecek, S. P. Antifungal Activity From 14-Helical b-Peptides. J. Am. Chem. Soc. 2006, 128(39), 12630–12631.
85. Lee, M.-R.; Raman, N.; Gellman, S. H.; Lynn, D. M.; Palecek, S. P. Hydrophobicity and Helicity Regulate the Antifungal Activity of 14-Helical b-Peptides. ACS Chem. Biol. 2014,
9(7), 1613–1621.
86. Akkarawongsa, R.; Potocky, T. B.; English, E. P.; Gellman, S. H.; Brandt, C. R. Inhibition of Herpes Simplex Virus Type 1 Infection by Cationic b-Peptides. Antimicrob. Agents
Chemother. 2008, 52(6), 2120–2129.
87. Choi, S.; Isaacs, A.; Clements, D.; Liu, D.; Kim, H.; Scott, R. W.; Winkler, J. D.; Degrado, W. F. De Novo Design and in vivo Activity of Conformationally Restrained Antimicrobial
Arylamide Foldamers. Proc. Natl. Acad. Sci. 2009, 106(17), 6968–6973.
88. Mensa, B.; Kim, Y. H.; Choi, S.; Scott, R.; Caputo, G. A.; Degrado, W. F. Antibacterial Mechanism of Action of Arylamide Foldamers. Antimicrob. Agents Chemother. 2011,
55(11), 5043–5053.
89. Mensa, B.; Howell, G. L.; Scott, R.; Degrado, W. F. Comparative Mechanistic Studies of Brilacidin, Daptomycin, and the Antimicrobial Peptide LL16. Antimicrob. Agents
Chemother. 2014, 58(9), 5136–5145.
90. Geueke, B.; Namoto, K.; Agarkova, I.; Perriard, J. C.; Kohler, H. P.E; Seebach, D. Bacterial Cell Penetration by b3-Oligohomoarginines: Indications for Passive Transfer Through
the Lipid Bilayer. ChemBioChem 2005, 6(6), 982–985.
91. Umezawa, N.; Gelman, M. A.; Haigis, M. C.; Raines, R. T.; Gellman, S. H. Translocation of a b-Peptide Across Cell Membranes. J. Am. Chem. Soc. 2002, 124(3), 368–369.
92. Seebach, D.; Namoto, K.; Mahajan, Y. R.; Bindscha¨dler, P.; Sustmann, R.; Kirsch, M.; Ryder, N. S.; Weiss, M.; Sauer, M.; Roth, C. Chemical and Biological Investigations of
b-Oligoarginines. Chem. Biodivers. 2004, 1(1), 65–97.
93. Hitz, T.; Iten, R.; Gardiner, J.; Namoto, K.; Walde, P.; Seebach, D. Interaction of a-and b-Oligoarginine-Acids and Amides With Anionic Lipid Vesicles: A Mechanistic and
Thermodynamic Study. Biochemistry 2006, 45(18), 5817–5829.
94. Potocky, T. B.; Menon, A. K.; Gellman, S. H. Cytoplasmic and Nuclear Delivery of a TAT-Derived Peptide and a b-Peptide After Endocytic Uptake Into HeLa Cells. J. Biol. Chem.
2003, 278(50), 50188–50194.
95. Potocky, T. B.; Silvius, J.; Menon, A. K.; Gellman, S. H. HeLa Cell Entry by Guanidinium-Rich b-Peptides: Importance of Specific Cation–Cell Surface Interactions. ChemBioChem
2007, 8(8), 917–926.
96. Patikoglou, G.; Burley, S. Eukaryotic Transcription Factor-DNA Complexes. Annu. Rev. Biophys. Biomol. Struct. 1997, 26(1), 289–325.
97. Au13Blackburn, G. M. Nucleic Acids in Chemistry and Biology ; Royal Society of Chemistry: Cambridge, UK, 2006.
Comp. by: MSanthiya Stage: Proof Chapter No.: 12547 Title Name: SMC2
Date:25/6/16 Time:06:54:38 Page Number: 24
24 Molecular Recognition Using Foldamers
SMC2: 12547
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only by the author(s), editor(s), reviewer(s), Elsevier and
typesetter SPi. It is not allowed to publish this proof online or in print. This proof copy is the copyright property of the publisher and is confidential until formal publication.
These proofs may contain colour figures. Those figures may print black and white in the final printed book if a colour print product has not been planned. The colour figures will appear in
colour in all electronic versions of this book.
98. Kimmerlin, T.; Namoto, K.; Seebach, D. Evidence From Circular Dichroism and From Melting Behavior for Helix-Inducing Complexation of a Designed b3-Pentadecapeptide
With DNA Duplexes. Preliminary Communication. Helv. Chim. Acta 2003, 86(6), 2104–2109.
99. Namoto, K.; Gardiner, J.; Kimmerlin, T.; Seebach, D. Investigation of the Interactions of b-Peptides With DNA Duplexes by Circular Dichroism Spectroscopy. Helv. Chim. Acta
2006, 89(12), 3087–3103.
100. Mu¨ller, S.; Laxmi-Reddy, K.; Jena, P. V.; Baptiste, B.; Dong, Z.; Godde, F.; Ha, T.; Rodriguez, R.; Balasubramanian, S.; Huc, I. Targeting DNA G-Quadruplexes With Helical Small
Molecules. ChemBioChem 2014, 15(17), 2563–2570.
101. Douat, C.; Aisenbrey, C.; Antunes, S.; Decossas, M.; Lambert, O.; Bechinger, B.; Kichler, A.; Guichard, G. A Cell-Penetrating Foldamer With a Bioreducible Linkage for
Intracellular Delivery of DNA. Angew. Chem. Int. Ed. 2015, 54(38), 11133–11137.
102. Shirude, P. S.; Gillies, E. R.; Ladame, S.; Godde, F.; Shin-Ya, K.; Huc, I.; Balasubramanian, S. Macrocyclic and Helical Oligoamides As a New Class of G-Quadruplex Ligands.
J. Am. Chem. Soc. 2007, 129(39), 11890–11891.
103. Huppert, J. L.; Balasubramanian, S. G-Quadruplexes in Promoters Throughout the Human Genome. Nucleic Acids Res. 2007, 35(2), 406–413.
104. Parkinson, G. N.; Lee, M. P.; Neidle, S. Crystal Structure of Parallel Quadruplexes From Human Telomeric DNA. Nature 2002, 417(6891), 876–880.
105. Dausse, E.; Gomes, S. D.R; Toulme´, J.-J. Aptamers: A New Class of Oligonucleotides in the Drug Discovery Pipeline?Curr. Opin. Pharmacol. 2009, 9(5), 602–607.
106. Delaurie`re, L.; Dong, Z.; Laxmi-Reddy, K.; Godde, F.; Toulme´, J. J.; Huc, I. Deciphering Aromatic Oligoamide Foldamer–DNA Interactions. Angew. Chem. Int. Ed. 2012, 51(2),
473–477.
107. Midoux, P.; Pichon, C.; Yaouanc, J. J.; Jaffre`s, P. A. Chemical Vectors for Gene Delivery: A Current Review on Polymers, Peptides and Lipids Containing Histidine or Imidazole
As Nucleic Acids Carriers. Br. J. Pharmacol. 2009, 157(2), 166–178.
108. Murphy, J. E.; Uno, T.; Hamer, J. D.; Cohen, F. E.; Dwarki, V.; Zuckermann, R. N. A Combinatorial Approach to the Discovery of Efficient Cationic Peptoid Reagents for Gene
Delivery. Proc. Natl. Acad. Sci. 1998, 95(4), 1517–1522.
109. Kao, S.-Y.; Calman, A. F.; Luciw, P. A.; Peterlin, B. M. Anti-Termination of Transcription Within the Long Terminal Repeat of HIV-1 by tat Gene Product. Nature 1987,
330(6147), 489–493.
110. Kesavan, V.; Tamilarasu, N.; Cao, H.; Rana, T. M. A New Class of RNA-Binding Oligomers: Peptoid Amide and Ester Analogues. Bioconjug. Chem. 2002, 13(6), 1171–1175.
111. Tamilarasu, N.; Huq, I.; Rana, T. M. High Affinity and Specific Binding of HIV-1 TAR RNA by a Tat-Derived Oligourea. J. Am. Chem. Soc. 1999, 121(7), 1597–1598.
112. Wang, X.; Huq, I.; Rana, T. M. HIV-1 TAR RNA Recognition by an Unnatural Biopolymer. J. Am. Chem. Soc. 1997, 119(27), 6444–6445.
113. Gelman, M. A.; Richter, S.; Cao, H.; Umezawa, N.; Gellman, S. H.; Rana, T. M. Selective Binding of TAR RNA by a Tat-Derived b-Peptide. Org. Lett. 2003, 5(20), 3563–3565.
114. Che`ne, P. Inhibiting the p53–MDM2 Interaction: An Important Target for Cancer Therapy. Nat. Rev. Cancer 2003, 3(2), 102–109.
115. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor
Transactivation Domain. Science 1996, 274(5289), 948–953.
116. Schon, O.; Friedler, A.; Bycroft, M.; Freund, S. M.V; Fersht, A. R. Molecular Mechanism of the Interaction Between MDM2 and p53. J. Mol. Biol. 2002, 323(3), 491–501.
117. Bo¨ttger, A.; Bo¨ttger, V.; Garcia-Echeverria, C.; Che`ne, P.; Hochkeppel, H.-K.; Sampson, W.; Ang, K.; Howard, S. F.; Picksley, S. M.; Lane, D. P. Molecular Characterization of the
hdm2-p53 Interaction. J. Mol. Biol. 1997, 269(5), 744–756.
118. Massova, I.; Kollman, P. A. Computational Alanine Scanning to Probe ProteinProtein Interactions: A Novel Approach to Evaluate Binding Free Energies. J. Am. Chem. Soc.
1999, 121(36), 8133–8143.
119. Kritzer, J. A.; Lear, J. D.; Hodsdon, M. E.; Schepartz, A. Helical b-Peptide Inhibitors of the p53-hDM2 Interaction. J. Am. Chem. Soc. 2004, 126(31), 9468–9469.
120. Kritzer, J. A.; Tirado-Rives, J.; Hart, S. A.; Lear, J. D.; Jorgensen, W. L.; Schepartz, A. Relationship Between Side Chain Structure and 14-Helix Stability of b3-Peptides in Water.
J. Am. Chem. Soc. 2005, 127(1), 167–178.
121. Harker, E. A.; Daniels, D. S.; Guarracino, D. A.; Schepartz, A. b-Peptides With Improved Affinity for hDM2 and hDMX. Bioorg. Med. Chem. 2009, 17(5), 2038–2046.
122. Jones, S. W.; Christison, R.; Bundell, K.; Voyce, C. J.; Brockbank, S. M.V; Newham, P.; Lindsay, M. A. Characterisation of Cell-Penetrating Peptide-Mediated Peptide Delivery.
Br. J. Pharmacol. 2005, 145(8), 1093–1102.
123. Harker, E. A.; Schepartz, A. Cell-Permeable b-Peptide Inhibitors of p53/hDM2 Complexation. ChemBioChem 2009, 10(6), 990–993.
124. Bautista, A. D.; Appelbaum, J. S.; Craig, C. J.; Michel, J.; Schepartz, A. Bridged b3-Peptide Inhibitors of p53-hDM2 Complexation: Correlation Between Affinity and Cell
Permeability. J. Am. Chem. Soc. 2010, 132(9), 2904–2906.
125. Plante, J. P.; Burnley, T.; Malkova, B.; Webb, M. E.; Warriner, S. L.; Edwards, T. A.; Wilson, A. J. Oligobenzamide Proteomimetic Inhibitors of the p53-hDM2 Protein-Protein
Interaction. Chem. Commun. 2009, 34, 5091–5093.
126. Hara, T.; Durell, S. R.; Myers, M. C.; Appella, D. H. Probing the Structural Requirements of Peptoids That Inhibit HDM2-p53 Interactions. J. Am. Chem. Soc. 2006, 128(6),
1995–2004.
127. Dharap, S. S.; Chandna, P.; Wang, Y.; Khandare, J. J.; Qiu, B.; Stein, S.; Minko, T. Molecular Targeting of BCL2 and BCLXL Proteins by Synthetic BCL2 Homology 3 Domain
Peptide Enhances the Efficacy of Chemotherapy. J. Pharmacol. Exp. Ther. 2006, 316(3), 992–998.
128. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E.; Eberstadt, M.; Yoon, H. S.; Shuker, S. B.; Chang, B. S.; Minn, A. J.; Thompson, C. B.; Fesik, S. W. Structure
of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis. Science 1997, 275(5302), 983–986.
129. Sadowsky, J. D.; Schmitt, M. A.; Lee, H.-S.; Umezawa, N.; Wang, S.; Tomita, Y.; Gellman, S. H. Chimeric (a/b+a)-Peptide Ligands for the BH3-Recognition Cleft of Bcl-xL:
Critical Role of the Molecular Scaffold in Protein Surface Recognition. J. Am. Chem. Soc. 2005, 127(34), 11966–11968.
130. Lee, E. F.; Sadowsky, J. D.; Smith, B. J.; Czabotar, P. E.; Peterson-Kaufman, K. J.; Colman, P. M.; Gellman, S. H.; Fairlie, W. D. High-Resolution Structural Characterization of a
Helical a/b-Peptide Foldamer Bound to the Anti-Apoptotic Protein Bcl-xL. Angew. Chem. 2009, 121(24), 4382–4386.
131. Boersma, M. D.; Haase, H. S.; Peterson-Kaufman, K. J.; Lee, E. F.; Clarke, O. B.; Colman, P. M.; Smith, B. J.; Horne, W. S.; Fairlie, W. D.; Gellman, S. H. Evaluation of Diverse
a/b-Backbone Patterns for Functional a-Helix Mimicry: Analogues of the Bim BH3 Domain. J. Am. Chem. Soc. 2012, 134(1), 315–323.
132. Sadowsky, J. D.; Fairlie, W. D.; Hadley, E. B.; Lee, H.-S.; Umezawa, N.; Nikolovska-Coleska, Z.; Wang, S.; Huang, D. C.S; Tomita, Y.; Gellman, S. H. (a/b+a)-Peptide
Antagonists of BH3 Domain/Bcl-xL Recognition: Toward General Strategies for Foldamer-Based Inhibition of Protein–Protein Interactions. J. Am. Chem. Soc. 2007, 129(1),
139–154.
133. Horne, W. S.; Boersma, M. D.; Windsor, M. A.; Gellman, S. H. Sequence-Based Design of a/b-Peptide Foldamers That Mimic BH3 Domains. Angew. Chem. Int. Ed. 2008,
47(15), 2853–2856.
134. Checco, J. W.; Lee, E. F.; Evangelista, M.; Sleebs, N. J.; Rogers, K.; Pettikiriarachchi, A.; Kershaw, N. J.; Eddinger, G. A.; Belair, D. G.; Wilson, J. L.; Eller, C. H.; Raines, R. T.;
Murphy, W. L.; Smith, B. J.; Gellman, S. H.; Fairlie, W. D. a/b-Peptide Foldamers Targeting Intracellular Protein–Protein Interactions With Activity in Living Cells. J. Am. Chem.
Soc. 2015, 137(35), 11365–11375.
135. Bennett, J. S. Structure and Function of the Platelet Integrin a(IIb)b(3). J. Clin. Investig. 2005, 115(12), 3363–3369.
136. Yin, H.; Slusky, J. S.; Berger, B. W.; Walters, R. S.; Vilaire, G.; Litvinov, R. I.; Lear, J. D.; Caputo, G. A.; Bennett, J. S.; Degrado, W. F. Computational Design of Peptides That
Target Transmembrane Helices. Science 2007, 315(5820), 1817–1822.
137. Shandler, S. J.; Korendovych, I. V.; Moore, D. T.; Smith-Dupont, K. B.; Streu, C. N.; Litvinov, R. I.; Billings, P. C.; Gai, F.; Bennett, J. S.; Degrado, W. F. Computational Design of
a b-Peptide That Targets Transmembrane Helices. J. Am. Chem. Soc. 2011, 133(32), 12378–12381.
138. De Strooper, B.; Vassar, R.; Golde, T. The Secretases: Enzymes With Therapeutic Potential in Alzheimer Disease. Nat. Rev. Neurol. 2010, 6(2), 99–107.
139. Das, C.; Berezovska, O.; Diehl, T. S.; Genet, C.; Buldyrev, I.; Tsai, J.-Y.; Hyman, B. T.; Wolfe, M. S. Designed Helical Peptides Inhibit an Intramembrane Protease. J. Am. Chem.
Soc. 2003, 125(39), 11794–11795.
Comp. by: MSanthiya Stage: Proof Chapter No.: 12547 Title Name: SMC2
Date:25/6/16 Time:06:54:39 Page Number: 25
Molecular Recognition Using Foldamers 25
SMC2: 12547
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only by the author(s), editor(s), reviewer(s), Elsevier and
typesetter SPi. It is not allowed to publish this proof online or in print. This proof copy is the copyright property of the publisher and is confidential until formal publication.
These proofs may contain colour figures. Those figures may print black and white in the final printed book if a colour print product has not been planned. The colour figures will appear in
colour in all electronic versions of this book.
140. Kornilova, A. Y.; Bihel, F.; Das, C.; Wolfe, M. S. The Initial Substrate-Binding Site of Gamma-Secretase is Located on Presenilin Near the Active Site. Proc. Natl. Acad. Sci. U. S.
A. 2005, 102(9), 3230–3235.
141. Imamura, Y.; Watanabe, N.; Umezawa, N.; Iwatsubo, T.; Kato, N.; Tomita, T.; Higuchi, T. Inhibition of g-Secretase Activity by Helical b-Peptide Foldamers. J. Am. Chem. Soc.
2009, 131(21), 7353–7359.
142. Imamura, Y.; Umezawa, N.; Osawa, S.; Shimada, N.; Higo, T.; Yokoshima, S.; Fukuyama, T.; Iwatsubo, T.; Kato, N.; Tomita, T.; Higuchi, T. Effect of Helical Conformation and Side
Chain Structure on g-Secretase Inhibition by b-Peptide Foldamers: Insight Into Substrate Recognition. J. Med. Chem. 2013, 56(4), 1443–1454.
143. Weissenhorn, W.; Dessen, A.; Harrison, S. C.; Skehel, J. J.; Wiley, D. C. Atomic Structure of the Ectodomain From HIV-1 gp41. Nature 1997, 387(6631), 426–430.
144. Moore, J. P.; Doms, R. W. The Entry of Entry Inhibitors: A Fusion of Science and Medicine. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(19), 10598–10602.
145. Matthews, T.; Salgo, M.; Greenberg, M.; Chung, J.; Demasi, R.; Bolognesi, D. Enfuvirtide: The First Therapy to Inhibit the Entry of HIV-1 Into Host CD4 Lymphocytes. Nat. Rev.
Drug Discov. 2004, 3(3), 215–225.
146. Stephens, O. M.; Kim, S.; Welch, B. D.; Hodsdon, M. E.; Kay, M. S.; Schepartz, A. Inhibiting HIV Fusion With a b-Peptide Foldamer. J. Am. Chem. Soc. 2005, 127(38),
13126–13127.
147. Bautista, A. D.; Stephens, O. M.; Wang, L.; Domaoal, R. A.; Anderson, K. S.; Schepartz, A. Identification of a b3-Peptide HIV Fusion Inhibitor With Improved Potency in Live
Cells. Bioorg. Med. Chem. Lett. 2009, 19(14), 3736–3738.
148. Johnson, L. M.; Horne, W. S.; Gellman, S. H. Broad Distribution of Energetically Important Contacts Across an Extended Protein Interface. J. Am. Chem. Soc. 2011, 133(26),
10038–10041.
149. Horne, W. S.; Johnson, L. M.; Ketas, T. J.; Klasse, P. J.; Lu, M.; Moore, J. P.; Gellman, S. H. Structural and Biological Mimicry of Protein Surface Recognition by Alpha/Beta-
Peptide Foldamers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(35), 14751–14756.
150. Johnson, L. M.; Mortenson, D. E.; Yun, H. G.; Horne, W. S.; Ketas, T. J.; Lu, M.; Moore, J. P.; Gellman, S. H. Enhancement of a-Helix Mimicry by an a/b-Peptide Foldamer Via
Incorporation of a Dense Ionic Side-Chain Array. J. Am. Chem. Soc. 2012, 134(17), 7317–7320.
151. Watkins, A. M.; Arora, P. S. Anatomy of b-Strands at Protein–Protein Interfaces. ACS Chem. Biol. 2014, 9(8), 1747–1754.
152. Lengyel, G. A.; Frank, R. C.; Horne, W. S. Hairpin Folding Behavior of Mixed Alpha/Beta-Peptides in Aqueous Solution. J. Am. Chem. Soc. 2011, 133(12), 4246–4249.
153. Griffioen, A.; Van Der Schaft, D.; Barendsz-Janson, A.; Cox, A.; Struijker, B. H.; Hillen, H.; Mayo, K. Anginex, a Designed Peptide That Inhibits Angiogenesis. Biochem. J. 2001,
354, 233–242.
154. Wang, J. B.; De Wang, M.; Li, E. X.; Dong, D. F. Advances and Prospects of Anginex as a Promising Anti-Angiogenesis and Anti-Tumor Agent. Peptides 2012, 38(2), 457–462.
155. Dings, R.; Arroyo, M.; Lockwood, N.; Van Eijk, L.; Haseman, J.; Griffioen, A.; Mayo, K. Beta-Sheet is the Bioactive Conformation of the Anti-Angiogenic Anginex Peptide.
Biochem. J. 2003, 373, 281–288.
156. Hegedu¨s, Z.; Makra, I.; Imre, N.; Hete´nyi, A.; Ma´ndity, I. M.; Monostori, E´.; Martinek, T. A. Foldameric Probes for Membrane Interactions by Induced b-Sheet Folding. Chem.
Commun. 2016, 52(9), 1891–1894.
157. Shankar, G. M.; Li, S.; Mehta, T. H.; Garcia-Munoz, A.; Shepardson, N. E.; Smith, I.; Brett, F. M.; Farrell, M. A.; Rowan, M. J.; Lemere, C. A.; Regan, C. M.; Walsh, D. M.;
Sabatini, B. L.; Selkoe, D. J. Amyloid-[Beta] Protein Dimers Isolated Directly From Alzheimer’s Brains Impair Synaptic Plasticity and Memory. Nat. Med. 2008, 14(8), 837–842.
158. Walsh, D. M.; Selkoe, D. J. Deciphering the Molecular Basis of Memory Failure in Alzheimer’s Disease. Neuron 2004, 44(1), 181–193.
159. Bett, C. K.; Ngunjiri, J. N.; Serem, W. K.; Fontenot, K. R.; Hammer, R. P.; Mccarley, R. L.; Garno, J. C. Structure–Activity Relationships in Peptide Modulators of b-Amyloid
Protein Aggregation: Variation in a,a-Disubstitution Results in Altered Aggregate Size and Morphology. ACS Chem. Neurosci. 2010, 1(9), 608–626.
160. Chen, Z.; Krause, G.; Reif, B. Structure and Orientation of Peptide Inhibitors Bound to Beta-Amyloid Fibrils. J. Mol. Biol. 2005, 354(4), 760–776.
161. Woods, R. J.; Brower, J. O.; Castellanos, E.; Hashemzadeh, M.; Khakshoor, O.; Russu, W. A.; Nowick, J. S. Cyclic Modular b-Sheets. J. Am. Chem. Soc. 2007, 129(9),
2548–2558.
162. Cheng, P. N.; Liu, C.; Zhao, M.; Eisenberg, D.; Nowick, J. S. Amyloid Beta-Sheet Mimics That Antagonize Protein Aggregation and Reduce Amyloid Toxicity. Nat. Chem. 2012,
4(11), 927–933.
163. Nowick, J. S.; Lam, K. S.; Khasanova, T. V.; Kemnitzer, W. E.; Maitra, S.; Mee, H. T.; Liu, R. An Unnatural Amino Acid That Induces b-Sheet Folding and Interaction in Peptides.
J. Am. Chem. Soc. 2002, 124(18), 4972–4973.
164. Ferrara, N.; Kerbel, R. S. Angiogenesis as a Therapeutic Target. Nature 2005, 438(7070), 967–974.
165. Ferrara, N.; Hillan, K. J.; Gerber, H.-P.; Novotny, W. Discovery and Development of Bevacizumab, an Anti-VEGF Antibody for Treating Cancer. Nat. Rev. Drug Discov. 2004, 3(5),
391–400.
166. Haase, H. S.; Peterson-Kaufman, K. J.; Lan Levengood, S. K.; Checco, J. W.; Murphy, W. L.; Gellman, S. H. Extending Foldamer Design Beyond a-Helix Mimicry: a/b-Peptide
Inhibitors of Vascular Endothelial Growth Factor Signaling. J. Am. Chem. Soc. 2012, 134(18), 7652–7655.
167. Fairbrother, W. J.; Christinger, H. W.; Cochran, A. G.; Fuh, G.; Keenan, C. J.; Quan, C.; Shriver, S. K.; Tom, J. Y.; Wells, J. A.; Cunningham, B. C. Novel Peptides Selected to Bind
Vascular Endothelial Growth Factor Target the Receptor-Binding Site. Biochemistry 1998, 37(51), 17754–17764.
168. Lo¨fblom, J.; Feldwisch, J.; Tolmachev, V.; Carlsson, J.; Sta˚hl, S.; Frejd, F. Y. Affibody Molecules: Engineered Proteins for Therapeutic, Diagnostic and Biotechnological
Applications. FEBS Lett. 2010, 584(12), 2670–2680.
169. Deisenhofer, J. Crystallographic Refinement and Atomic Models of a Human Fc Fragment and Its Complex With Fragment B of Protein A From Staphylococcus aureus at 2.9-
and 2.8-.ANG. Resolution. Biochemistry 1981, 20(9), 2361–2370.
170. Nord, K.; Gunneriusson, E.; Ringdahl, J.; Sta˚hl, S.; Uhle´n, M.; Nygren, P.-A˚. Binding Proteins Selected From Combinatorial Libraries of an a-Helical Bacterial Receptor Domain.
Nat. Biotechnol. 1997, 15(8), 772–777.
171. Fedorova, A.; Zobel, K.; Gill, H. S.; Ogasawara, A.; Flores, J. E.; Tinianow, J. N.; Vanderbilt, A. N.; Wu, P.; Meng, Y. G.; Williams, S.-P. The Development of Peptide-Based Tools
for the Analysis of Angiogenesis. Chem. Biol. 2011, 18(7), 839–845.
172. Jonsson, A.; Wa˚llberg, H.; Herne, N.; Sta˚hl, S.; Frejd, F. Y. Generation of Tumour-Necrosis-Factor-a-Specific Affibody Molecules Capable of Blocking Receptor Binding In Vitro.
Biotechnol. Appl. Biochem. 2009, 54(2), 93–103.
173. Checco, J. W.; Kreitler, D. F.; Thomas, N. C.; Belair, D. G.; Rettko, N. J.; Murphy, W. L.; Forest, K. T.; Gellman, S. H. Targeting Diverse Protein–Protein Interaction Interfaces With
a/b-Peptides Derived From the Z-Domain Scaffold. Proc. Natl. Acad. Sci. 2015, 112(15), 4552–4557.
174. Lagerstrom, M. C.; Schioth, H. B. Structural Diversity of G Protein-Coupled Receptors and Significance for Drug Discovery. Nat. Rev. Drug Discov. 2008, 7(4), 339–357.
175. Gademann, K.; Ernst, M.; Hoyer, D.; Seebach, D. Synthesis and Biological Evaluation of a Cyclo-b-tetrapeptide as a Somatostatin Analogue. Angew. Chem. Int. Ed. 1999, 38(9),
1223–1226.
176. Cabrele, C.; Martinek, T. S.A; Reiser, O.; Berlicki, Ł. Peptides Containing b-Amino Acid Patterns: Challenges and Successes in Medicinal Chemistry. J. Med. Chem. 2014,
57(23), 9718–9739.
177. Vilardaga, J.-P.; Romero, G.; Friedman, P. A.; Gardella, T. J. Molecular Basis of Parathyroid Hormone Receptor Signaling and Trafficking: A Family B GPCR Paradigm. Cell. Mol.
Life Sci. 2011, 68(1), 1–13.
178. Cheloha, R. W.; Maeda, A.; Dean, T.; Gardella, T. J.; Gellman, S. H. Backbone Modification of a Polypeptide Drug Alters Duration of Action In Vivo. Nat. Biotechnol. 2014, 32(7),
653–655.
179. Denton, E. V.; Craig, C. J.; Pongratz, R. L.; Appelbaum, J. S.; Doerner, A. E.; Narayanan, A.; Shulman, G. I.; Cline, G. W.; Schepartz, A. A b-Peptide Agonist of the GLP-1
Receptor, a Class B GPCR. Org. Lett. 2013, 15(20), 5318–5321.
180. Johnson, L. M.; Barrick, S.; Hager, M. V.; Mcfedries, A.; Homan, E. A.; Rabaglia, M. E.; Keller, M. P.; Attie, A. D.; Saghatelian, A.; Bisello, A. A Potent a/b-Peptide Analogue of
GLP-1 With Prolonged Action In Vivo. J. Am. Chem. Soc. 2014, 136(37), 12848–12851.
Comp. by: MSanthiya Stage: Proof Chapter No.: 12547 Title Name: SMC2
Date:25/6/16 Time:06:54:39 Page Number: 26
26 Molecular Recognition Using Foldamers
SMC2: 12547
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only by the author(s), editor(s), reviewer(s), Elsevier and
typesetter SPi. It is not allowed to publish this proof online or in print. This proof copy is the copyright property of the publisher and is confidential until formal publication.
These proofs may contain colour figures. Those figures may print black and white in the final printed book if a colour print product has not been planned. The colour figures will appear in
colour in all electronic versions of this book.
181. Jones, G.; Hashim, R.; Power, D. A Comparison of the Strength of Binding of Antithrombin III, Protamine and Poly(L-lysine) to Heparin Samples of Different Anticoagulant
Activities. Biochim. Biophys. Acta 1986, 883(1), 69–76.
182. Choi, S.; Clements, D. J.; Pophristic, V.; Ivanov, I.; Vemparala, S.; Bennett, J. S.; Klein, M. L.; Winkler, J. D.; Degrado, W. F. The Design and Evaluation of Heparin-Binding
Foldamers. Angew. Chem. Int. Ed. 2005, 44(41), 6685–6689.
183. Montalvo, G. L.; Zhang, Y.; Young, T. M.; Costanzo, M. J.; Freeman, K. B.; Wang, J.; Clements, D. J.; Magavern, E.; Kavash, R. W.; Scott, R. W. De Novo Design of Self-
Assembling Foldamers That Inhibit Heparin–Protein Interactions. ACS Chem. Biol. 2014, 9(4), 967–975.
184. Norgren, A. S.; Geitmann, M.; Danielson, U. H.; Arvidsson, P. I. Biomolecular Recognition of Glycosylated b3-Peptides by GalNAc Specific Lectins. J. Mol. Recognit. 2007,
20(2), 132–138.
185. Kaszowska, M.; Norgren, A. S.; Arvidson, P. I.; Sandstro¨m, C. Studies on the Interactions Between Glycosylated b3-Peptides and the Lectin Vicia villosa by Saturation Transfer
Difference NMR Spectroscopy. Carbohydr. Res. 2009, 344(18), 2577–2580.
186. Siriwardena, A.; Pulukuri, K. K.; Kandiyal, P. S.; Roy, S.; Bande, O.; Ghosh, S.; Garcia Ferna´ndez, J. M.; Ariel Martin, F.; Ghigo, J. M.; Beloin, C. Sugar-Modified Foldamers as
Conformationally Defined and Biologically Distinct Glycopeptide Mimics. Angew. Chem. Int. Ed. 2013, 52(39), 10221–10226.
Comp. by: MSanthiya Stage: Proof Chapter No.: 12547 Title Name: SMC2
Date:25/6/16 Time:06:54:40 Page Number: 27
Molecular Recognition Using Foldamers 27
SMC2: 12547
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only by the author(s), editor(s), reviewer(s), Elsevier and
typesetter SPi. It is not allowed to publish this proof online or in print. This proof copy is the copyright property of the publisher and is confidential until formal publication.
These proofs may contain colour figures. Those figures may print black and white in the final printed book if a colour print product has not been planned. The colour figures will appear in
colour in all electronic versions of this book.
